Teligent (TLGTQ) 10-K 31 Mar 14 2013 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Jun. 28, 2013	Mar. 25, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'IGI Laboratories, Inc.	'	'
Document Type	'10-K	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Common Stock, Shares Outstanding	'	'	47,019,121
Entity Public Float	'	$32,500,000	'
Amendment Flag	'false	'	'
Entity Central Index Key	'0000352998	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$2,101,000	$2,536,000
Accounts receivable, net	4,947,000	1,577,000
Inventories	2,869,000	1,773,000
Prepaid expenses and other receivables	641,000	253,000
Total current assets	10,558,000	6,139,000
Property, plant and equipment, net	2,623,000	2,691,000
Product acquisition costs, net	1,766,000	'
Restricted cash, long term	54,000	54,000
License fee, net	200,000	300,000
Debt issuance costs, net	69,000	100,000
Other	157,000	143,000
Total assets	15,427,000	9,427,000
Current liabilities:	'	'
Accounts payable	1,523,000	1,091,000
Accrued expenses	2,915,000	820,000
Deferred income, current	768,000	48,000
Capital lease obligation, current	15,000	17,000
Total current liabilities	5,221,000	1,976,000
Note payable, bank	3,000,000	1,000,000
Deferred income, long term	4,000	20,000
Capital lease obligation, long term	11,000	4,000
Total liabilities	8,236,000	3,000,000
Stockholders’ equity:	'	'
Common stock, $0.01 par value, 60,000,000 shares authorized; 46,748,575 and 42,705,032 shares issued and outstanding as of December 31, 2013 and 2012, respectively	487,000	446,000
Additional paid-in capital	51,541,000	47,409,000
Accumulated deficit	-44,837,000	-43,445,000
Total stockholders’ equity	7,191,000	6,427,000
Total liabilities and stockholders' equity	15,427,000	9,427,000
Series A Preferred Stock [Member]	'	'
Stockholders’ equity:	'	'
Convertible Preferred Stock	'	500,000
Series C Preferred Stock [Member]	'	'
Stockholders’ equity:	'	'
Convertible Preferred Stock	'	$1,517,000

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
			Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]
Convertible Preferred stock liquidation preference (in Dollars per share)	'	'	$0	$500,000	$0	$1,764,240
Convertible Preferred Stock, par value (in Dollars per share)	'	$0.01	$0.01	$0.01	$0.01	$0.01
Convertible Preferred Stock, shares authorized	'	1,000,000	100	100	1,550	1,550
Convertible Preferred Stock, shares issued	'	'	0	50	0	1,550
Convertible Preferred Stock, shares outstanding	'	'	0	50	0	1,550
Common stock, par value (in Dollars per share)	$0.01	$0.01	'	'	'	'
Common stock, shares authorized	60,000,000	60,000,000	'	'	'	'
Common stock, shares issued	46,748,575	42,705,032	'	'	'	'
Common stock, shares outstanding	46,748,575	42,705,032	'	'	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Revenues:	'	'
Product sales, net	$16,981,000	$6,545,000
Research and development income	1,094,000	1,931,000
Licensing, royalty and other income	149,000	87,000
Total revenues	18,224,000	8,563,000
Costs and Expenses:	'	'
Cost of sales	12,079,000	5,787,000
Selling, general and administrative expenses	3,484,000	3,078,000
Product development and research expenses	2,743,000	2,834,000
Total costs and expenses	18,306,000	11,699,000
Operating loss	-82,000	-3,136,000
Interest expense and other income (expense), net	-199,000	-975,000
Loss before benefit from income taxes	-281,000	-4,111,000
Benefit from income taxes, principally sale of New Jersey net operating losses	197,000	184,000
Net loss	-84,000	-3,927,000
Deemed dividend upon mandatory conversion of preferred stock into common stock	-1,308,000	'
Net loss attributable to common stockholders	($1,392,000)	($3,927,000)
Basic and diluted loss per common share (in Dollars per share)	($0.03)	($0.10)
Weighted average shares of common stock outstanding	'	'
Basic and diluted (in Shares)	43,517,640	39,786,446

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:	'	'
Net loss	($84,000)	($3,927,000)
Reconciliation of net loss to net cash used in operating activities:	'	'
Depreciation and amortization	375,000	357,000
Amortization of license fee	100,000	100,000
Provision for write down of inventory	110,000	138,000
Stock-based compensation expense	536,000	378,000
Amortization of debt issuance costs	31,000	862,000
Amortization of product acquisition costs	60,000	'
Loss on abandonment of property	'	9,000
Changes in operating assets and liabilities:	'	'
Accounts receivable	-3,370,000	-369,000
Inventories	-1,206,000	-716,000
Prepaid expenses and other current assets	-402,000	119,000
Accounts payable and accrued expenses	2,528,000	671,000
Deferred income	704,000	5,000
Net cash used in operating activities	-618,000	-2,373,000
Cash flows from investing activities:	'	'
Capital expenditures	-287,000	-342,000
Product acquisition costs	-1,826,000	'
Net cash used in investing activities	-2,113,000	-342,000
Cash flows from financing activities:	'	'
Proceeds from note payable, net of debt issuance costs	2,000,000	886,000
Repayment of note payable, related party	'	-500,000
(Expenses of) proceeds from sale of treasury stock, net of expenses	-63,000	1,963,000
Proceeds from exercise of common stock options and warrants	376,000	39,000
Principal payments on capital lease obligation	-17,000	-51,000
Net cash provided by financing activities	2,296,000	2,337,000
Net decrease in cash and cash equivalents	-435,000	-378,000
Cash and cash equivalents at beginning of year	2,536,000	2,914,000
Cash and cash equivalents at end of year	2,101,000	2,536,000
Supplemental cash flow information:	'	'
Cash payments for interest	142,000	99,000
Cash receipt from taxes, net	-194,000	-184,000
Non cash transactions:	'	'
Equipment financed through capital lease	20,000	30,000
Issuance of restricted stock	3,000	1,000
Forfeiture of restricted stock	'	-2,000
Issuance of warrants	'	209,000
Series A Convertible Preferred Stock into Common Stock [Member]	'	'
Non cash transactions:	'	'
Conversion of Convertible Preferred Stock	500,000	'
Series C Convertible Preferred Stock and Accrued Dividends into Common Stock [Member]	'	'
Non cash transactions:	'	'
Conversion of Convertible Preferred Stock	$2,825,000	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholdersb Equity (USD $)

Restricted Stock [Member]

Restricted Stock [Member]

Common Stock Issued for Series A Convertible Preferred Stock [Member]

Common Stock Issued for Series A Convertible Preferred Stock [Member]

Common Stock Issued for Series A Convertible Preferred Stock [Member]

Common Stock Issued for Series C Convertible Preferred Stock Including Dividend [Member]

Common Stock Issued for Series C Convertible Preferred Stock Including Dividend [Member]

Common Stock Issued for Series C Convertible Preferred Stock Including Dividend [Member]

Common Stock Issued for Series C Convertible Preferred Stock Including Dividend [Member]

Fair Value Disclosure (Member)

Fair Value Disclosure (Member)

Series A Preferred Stock [Member]

Series C Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Treasury Stock [Member]

Stock Option Other Than Restricted Stock [Member]

Total

Additional Paid-in Capital [Member]

Series A Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Series C Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Additional Paid-in Capital [Member]

Stock Option Other Than Restricted Stock [Member]

Balance at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

$500,000

$1,517,000

$415,000

'

$46,246,000

($39,518,000)

($1,395,000)

'

$7,765,000

Balance (in Shares) at Dec. 31, 2011

'

'

'

'

'

'

'

'

'

'

'

50

1,550

41,463,836

'

'

'

'

'

'

Stock-based compensation expense

222,000

222,000

'

'

'

'

'

'

'

'

'

'

'

'

156,000

'

'

'

156,000

378,000

Restricted stock issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

-1,000

'

'

'

'

Restricted stock issuance (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

109,748

'

'

'

'

'

'

Restricted stock forfeited

'

'

'

'

'

'

'

'

'

'

'

'

'

-2,000

'

2,000

'

'

'

-2,000

Restricted stock forfeited (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

-177,084

'

'

'

'

'

'

Stock options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26,000

'

'

'

26,000

Stock options exercised (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

40,000

'

'

'

'

'

40,000

Warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

13,000

'

'

'

'

'

13,000

Warrants exercised (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

1,268,532

'

'

'

'

'

'

Sale of treasury stock, net of expenses of $36

'

'

'

'

'

'

'

'

'

'

'

'

'

19,000

'

549,000

'

1,395,000

'

1,963,000

Fair value of warrants issued

'

'

'

'

'

'

'

'

'

209,000

209,000

'

'

'

'

'

'

'

'

'

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,927,000

'

'

-3,927,000

Balance, December 31, 2013 at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

500,000

1,517,000

446,000

'

47,409,000

-43,445,000

'

'

6,427,000

Balance, December 31, 2013 (in Shares) at Dec. 31, 2012

'

'

'

'

'

'

'

'

'

'

'

50

1,550

42,705,032

'

'

'

'

'

'

Stock-based compensation expense

329,000

329,400

'

'

'

'

'

'

'

'

'

'

'

'

207,000

'

'

'

207,000

536,000

Restricted stock issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000

'

-3,000

'

'

'

'

Restricted stock issuance (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

325,000

'

'

'

'

'

'

Stock options exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

138,000

'

'

'

139,000

Stock options exercised (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

129,336

'

'

'

'

'

129,336

Costs related to stock issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-63,000

'

'

'

-63,000

Common stock issued

'

'

-500,000

5,000

495,000

-1,517,000

27,000

2,798,000

-1,308,000

'

'

'

'

'

'

'

'

'

'

'

Common stock issued (in Shares)

'

'

-50

500,000

'

-1,550

2,661,494

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

'

231,000

'

'

'

236,000

Warrants exercised (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

427,713

'

'

'

'

'

'

Net loss

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-84,000

'

'

-84,000

Balance, December 31, 2013 at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

$487,000

'

$51,541,000

($44,837,000)

'

'

$7,191,000

Balance, December 31, 2013 (in Shares) at Dec. 31, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

46,748,575

'

'

'

'

'

'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholdersb Equity (Parentheticals) (Common Stock [Member], Series C Preferred Stock [Member], USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Common Stock [Member] | Series C Preferred Stock [Member]	'
Deemed Dividend Series C Convertible Preferred Stock	$1,308

Note_1_Summary_of_Significant_

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	1.      Summary of Significant Accounting Policies
	Nature of the Business
	IGI Laboratories, Inc. is a Delaware corporation formed in 1977. On May 7, 2008, the stockholders of IGI, Inc. approved the name change of the Company from IGI, Inc. to IGI Laboratories, Inc. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets.
	Currently, we have two platforms for growth:
		■	Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in our own label in topical dosage forms; and,
		■	Increasing our current contract manufacturing and formulation services business.
	In addition, we will continue to explore ways to accelerate our growth through the creation of unique opportunities from the acquisition of additional intellectual property, and the expansion of the use of our existing intellectual property, including our licensed Novasome ® technology.
	To date, we have filed fourteen Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA for additional pharmaceutical products. We expect to continue to expand our presence in the generic topical pharmaceutical market through the filing of additional ANDAs with the FDA and the subsequent launch of products as these applications are approved. Our target is to file at least ten ANDAs in 2014 through our internal research and development program. On March 12, 2014, the Company received our first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. We will also seek to license or acquire further products, intellectual property, or ANDAs to expand our portfolio. On February 1, 2013, we acquired assets and intellectual property, including an ANDA, for econazole nitrate cream 1%, which we launched in September 2013.
	IGI also develops manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers as well as the OTC and cosmetic markets. These products are used in a wide range of applications from cosmetics and cosmeceuticals to the prescription treatment of conditions like dermatitis, psoriasis, and eczema.
	Principles of Consolidation
	The consolidated financial statements include the accounts of IGI Laboratories, Inc. and its wholly owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated.
	Cash Equivalents
	Cash equivalents consist of short-term investments, which have original maturities of 90 days or less.
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, notes payable, accounts payable, capital leases and other accrued liabilities at December 31, 2013 approximate their fair value for all periods presented.
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company extends credit to its contract services customers, based upon credit evaluations, in the normal course of business, primarily with 30-day terms. The Company does not require collateral from its customers. Bad debt provisions are provided for on the allowance method based on historical experience and management’s evaluation of outstanding accounts receivable. The Company reviews the allowance for doubtful accounts regularly, and past due balances are reviewed individually for collectability. The Company charges off uncollectible receivables against the allowance when the likelihood of collection is remote.
	The Company extends credit to wholesaler and distributor customers and national retail chain customers, based upon credit evaluations, in the normal course of business, primarily with 60-day terms. The Company maintains customer-related accruals and allowances that consist primarily of chargebacks, rebates, sales returns, shelf stock allowances, administrative fees and other incentive programs. Some of these adjustments relate specifically to the generic prescription pharmaceutical business. Typically, the aggregate gross-to-net adjustments related to these customers can exceed 50% of the gross sales through this distribution channel. Certain of these accruals and allowances are recorded in the balance sheet as current liabilities and others are recorded as a reduction in accounts receivable.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable.
	The Company maintains its cash in accounts with quality financial institutions. Although the Company currently believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to us, there is no assurance that those institutions will be able to continue to do so.
	In 2013, the Company had sales to three customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million, $2.2 million and $2.1 million, respectively, and aggregately represented 39% of total revenues. Accounts receivable related to the Company’s major customers comprised 11% of all accounts receivable as of December 31, 2013.
	In 2012, the Company had sales to two customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million and $1.8 million, respectively, and aggregately represented 54% of total revenues. Accounts receivable related to the Company’s major customers comprised 59% of all accounts receivable as of December 31, 2012.
	Inventories
	Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. The company records an inventory reserve for losses associated with dated and expired raw materials. This reserve is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. Management does not believe the Company’s inventory is subject to significant risk of obsolescence in the near term. Reserve for obsolescence included in inventory at December 31, 2013 and 2012 were $0.2 million and $0.1 million respectively.
	Property, Plant and Equipment
	Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows:
			Useful Lives
			(years)
	Buildings and improvements		10	-	30
	Machinery and equipment		3	-	10
	Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results.
	Intangible Assets
	Intangible assets consist of the cost of an acquired product and product rights. Intangible assets are amortized over fifteen years (the asset’s estimated useful life).
	Long-Lived Assets
	In accordance with the provisions of ASC 360-10-55, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In performing such review for recoverability, the Company compares expected future cash flows of assets to the carrying value of the long-lived assets and related identifiable intangibles. If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying value of the assets and their estimated fair value, with fair values being determined using projected discounted cash flows at the lowest level of cash flows identifiable in relation to the assets being reviewed. As of December 31, 2013, no impairments existed.
	Accrued Expenses
	Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. For the fiscal year ended December 31, 2013, the largest component of accrued expenses was accrued royalties of $945,000, accrued payroll of $704,000, accrued wholesaler fees of $624,500 and accrued directors’ fees of $214,500. For the fiscal year ended December 31, 2012, the largest component of accrued expenses was accrued payroll of $256,700, accrued directors’ fees of $209,900 and accrued consulting fees of $60,000.
	License Fee
	License fees are amortized on a straight-line basis over the life of the agreement (10 years).
	Accounting for Environmental Costs
	Accruals for environmental remediation are recorded when it is probable a liability has been incurred and costs are reasonably estimable. The estimated liabilities are recorded at undiscounted amounts. Environmental insurance recoveries are included in the statement of operations in the year in which the issue is resolved through settlement or other appropriate legal process.
	Income Taxes
	The Company records income taxes in accordance with ASC 740-10, “Accounting for Income Taxes,” under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to operating loss and tax credit carry forwards and differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded based on a determination of the ultimate realizability of future deferred tax assets. A valuation allowance equal to 100% of the net deferred tax assets has been recognized due to uncertainty regarding the future realization of these assets.
	The Company complies with the provisions of ASC 740-10-25 that clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements in accordance with ASC 740-10, “Accounting for Income Taxes,” and prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There were no unrecognized tax benefits as of the date of adoption. As such, there are no unrecognized tax benefits included in the balance sheet that would, if recognized, affect the effective tax rate.
	Revenue Recognition
	The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.
	The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.
	Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.
	IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.
	Revenue and Provision for Sales Returns and Allowances
	As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.
	The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.
	Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.
	Gross-To-Net Sales Deductions
			Twelve Months Ended December 31,
			2013			2012
			(in thousands)			(in thousands)
	Gross IGI product sales		$	15,001		$	18
	Reduction to gross product sales:
	Chargebacks and billbacks			(6,050	)		-
	Sales discounts and other allowances			(1,593	)		(1	)
	Total reduction to gross product sales		$	(7,643	)	$	(1	)
Net IGI product sales		$	7,358		$	17
Accounts receivable are presented net of SRA balances of $1.9 million and $0 at December 31, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.6 million and $0 at December 31, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.9 million and $0 for the twelve month periods ended December 31 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with three of the four products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. The royalty is calculated based on contracted terms of 40% of net sales for the three products which is to be paid quarterly to the pharmaceutical partner. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.9 million and $0 at December 31, 2013 and 2012, respectively, related to these royalties. Royalty expense of $2.6 million and $0 was included in cost of goods sold for the twelve months ended December 31 for 2013, and 2012 respectively. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.
Contract Manufacturing Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products.
Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.
In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.
Stock-Based Compensation
ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the vesting period of the grant.
Debt Issuance Costs
Expenses related to debt financing activities are capitalized and amortized on a straight-line basis, which approximates the effective interest method, over the term of the loan. On August 1, 2012, the Company paid-off its existing credit facility with Amzak Capital Management, LLC, and wrote-off the unamortized debt issuance costs to interest expense. The Company entered into a new loan agreement with Square 1 Bank, and in connection with this financing the Company incurred and recorded debt issuance costs in the amount of $114,000, which will be amortized over the remaining life of the loan, 42 months.
Product Development and Research
The Company's research and development costs are expensed as incurred.
Advertising Costs
Advertising costs are expensed as incurred. Such expenses for the years ended December 31, 2013 and 2012 were $3,500 and $3,600, respectively.
Shipping and Handling Costs
Costs related to shipping and handling is comprised of outbound freight and the associated labor. These costs are recorded in costs of sales.
Net Loss per Common Share
Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the exercise of options and warrants and the conversion of preferred stock. Due to the net loss for the years ended December 31, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each year; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 2,998,046 for 2013 and 6,445,628 for 2012.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowances, stock based compensation and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
Recent Accounting Pronouncements
In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When A Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), which provides guidance on the presentation of unrecognized tax benefits when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. The amendments in this update are effective for fiscal years (and interim periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company does not expect ASU 2013-11 to have a material effect on its financial condition, results of operation or cash flows. This update will be effective for the Company for the year beginning January 1, 2014.

Note_2_Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	'
	2.      Liquidity
	The Company’s principal sources of liquidity are cash and cash equivalents of approximately $2,101,000 at December 31, 2013, the $2,000,000 available under the $5,000,000 credit facility detailed below and cash from operations. The Company sustained net losses attributable to common stockholders of $1,392,000 and $3,927,000 for the years ended December 31, 2013 and 2012, respectively, and had working capital of $5,337,000 at December 31, 2013.
	The Company’s business operations have been primarily funded over the past five years through private placements of its capital stock. The Company raised an aggregate of $2,000,000 through private placements of equity with accredited investors in 2012, $7,213,000 in 2010 and $5,304,000 in 2009 principally from private equity investors. The use of proceeds was intended for general working capital needs as well as the acquisition of econazole nitrate cream 1% which was purchased on February 1, 2013 and launched in November 2013. In August 2012, the Company also entered into a $3,000,000 line of credit. On July 26, 2013, the Company entered into an amendment to the loan and security agreement. The amendment increased the line of credit to $5,000,000 on December 31, 2013 upon the Company’s compliance with certain covenants (See Note 6). As of December 31, 2013 the outstanding balance on the line of credit was $3,000,000. The Company may require additional funding and this funding will depend, in part, on the timing and structure of potential business arrangements. If necessary, the Company may continue to seek to raise additional capital through the sale of its equity. It may be accomplished via a strategic alliance with a third party. There may also be additional acquisition and growth opportunities that may require external financing. There can be no assurance that such financing will be available on terms acceptable to the Company, or at all. The Company also has the ability to defer certain product development and other programs, if necessary. The Company believes that our existing capital resources will be sufficient to support its current business plan and operations beyond March 2015.

Note_3_License_Fee

Note 3 - License Fee	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Commitments Disclosure [Text Block]	'
	3.      License Fee
	On December 12, 2005, the Company extended its license agreement for an additional ten years with Novavax, Inc. for $1,000,000. This extension entitles the Company to exclusive use of the Novasome® lipid vesicle encapsulation and certain other technologies in the fields of (i) animal pharmaceuticals, biologicals and other animal health products; (ii) foods, food applications, nutrients and flavorings; (iii) cosmetics, consumer products and dermatological over-the-counter and prescription products (excluding certain topically delivered hormones); (iv) fragrances; and (v) chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals and other specialty chemicals, and the processes for making the same through 2015. This payment is being amortized ratably over the ten-year period. For the years ended, December 31, 2013 and 2012, the Company recorded a $100,000 expense in each year related to the amortization of the license. Amortization of this license fee will amount to $100,000 per year for 2014 and 2015.

Note_4_Inventories

Note 4 - Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	4.      Inventories
	Inventories as of December 31, 2013 and 2012 consisted of:
		2013		2012
		(in thousands)		(in thousands)
	Raw materials	$	2,172	$	1,673
	Work in progress		271		26
	Finished goods		426		74
		$	2,869	$	1,773

Note_5_Property_Plant_and_Equi

Note 5 - Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	5.      Property, Plant and Equipment
	Property, plant and equipment, at cost, as of December 31, 2013 and 2012, consisted of:
		2013			2012
		(in thousands)			(in thousands)
	Land	$	257		$	257
	Building and improvements		3,599			3,552
	Machinery and equipment		3,375			3,120
	Construction in progress		128			123
			7,359			7,052
	Less accumulated depreciation and amortization		(4,736	)		(4,361	)
	Property, plant and equipment, net	$	2,623		$	2,691
	The Company recorded depreciation and amortization expense of $375,000 and $357,000 in 2013 and 2012, respectively.

Note_6_Note_Payable

Note 6 - Note Payable	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	6. Note Payable
	On August 31, 2012, IGI Laboratories, Inc. and its subsidiaries entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Square 1 Bank (the “Lender”) pursuant to which the Lender agreed to extend credit facilities to the Company (the “Financing”). The Company drew down $1,000,000 in principal amount on August 31, 2012, $1,000,000 in principal amount on February 5, 2013 and $1,000,000 in principal amount on August 2, 2013. At December 31, 2013, $3,000,000 was outstanding.
	To secure payment of the amounts financed under the Loan and Security Agreement, the Company has granted to the Lender a continuing security interest in and against, generally, all of its tangible and intangible assets, except intellectual property.
	Under the Loan and Security Agreement, the Company can request revolving loan advances under (a) the Formula Revolving Line and (b) the Non-Formula Revolving Line, and term loan advances under the term loans. The aggregate total borrowings under the facilities cannot exceed the total borrowing limit of $3,000,000 at any one time outstanding. Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 1.9% above the prime rate then in effect, and (B) 5.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.15% above the prime rate then in effect, and (B) 5.9%. Term loan advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 2.4% above the prime rate then in effect, and (B) the rate in effect at December 31, 2013, which was 6.15%.
	The term of the Formula Revolving Line and the Non-Formula Revolving Line is one year from the date of the Loan and Security Agreement and can be extended by mutual agreement of the parties. The term of the term loans is 42 months from the date of the Loan and Security Agreement, but term loan advances are available to the Company only until February 28, 2014.
	In accordance with the Loan and Security Agreement, the Company had to maintain a liquidity ratio of at least 1.25 to 1.00 (the “LQR Threshold”), provided that the LQR Threshold was reduced to 1.00 so long as the Company had achieved minimum Revenue, measured monthly on a trailing three month basis, of at least the amounts listed in the document for the corresponding reporting periods. To further clarify, if at any time the Company is not in compliance with the minimum revenue amounts set forth below, the LQR Threshold would be increased to 1.25 to 1.00. “Liquidity” means the sum of: (i) unrestricted cash in bank plus (ii) the Borrowing Base (the amount drawn to date). In accordance with the Loan and Security Agreement, liquidity ratio means the ratio of Liquidity to all Indebtedness to the Lender (but excluding any Indebtedness to the Lender which is secured by cash held in a segregated deposit account at the Lender). As of December 31, 2013, the Company was in compliance with the LQR Threshold required under the Loan and Security Agreement.
	On July 26, 2013, the Company entered into an Amendment to the Loan and Security Agreement (the “Amendment”). In accordance with the Amendment, notwithstanding the existing LQR Thresholds, for so long as the Company is in compliance with the minimum revenue requirements established in this Amendment, the Company shall be permitted to maintain a liquidity ratio of not less than .90 to 1.00 for a continuous 60 day period every 12 months. In connection with the lower liquidity ratio, in accordance with the Amendment, under the Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 4.9% above the prime rate then in effect, and (B) 8.65%. Non-Formula Revolving Line advances shall bear interest, on the outstanding balance thereof, at a variable rate equal to the greater of (A) 5.15% above the prime rate then in effect, and (B) 8.9%, until such time that the lower liquidity ratio is no longer in place. The Company remained in compliance through the end of December of 2013, and as such the aggregate borrowing amount was increased from $3,000,000 to $5,000,000.
	In connection with the Financing, the Company paid in full its existing credit facility with Amzak Capital Management, LLC (see Note 7 below) and executed a Release and Termination Note and Credit Agreement with Amzak Capital Management, LLC to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010 (the “Amzak Credit Facility ”).

Note_7_Note_Payable_Related_Pa

Note 7 - Note Payable - Related Party	12 Months Ended
	Dec. 31, 2013
Note 7 - Note Payable - Related Party [Line Items]	'
Related Party Transactions Disclosure [Text Block]	'
	16.      Related Party Transactions
	For a description of the Company’s Private Placement and Credit Agreement with Amzak Capital Management, LLC, the related party, see Notes 7 and 17.
Credit Agreement (Member)	'
Note 7 - Note Payable - Related Party [Line Items]	'
Related Party Transactions Disclosure [Text Block]	'
	7.      Note Payable – Related Party
	On December 21, 2010, the Company entered into a Credit Agreement with Amzak Capital Management, LLC (the “Lender”) pursuant to which Amzak extended a $3,000,000 credit facility to the Company (the “Credit Agreement”).
	On August 31, 2012, the Company paid in full its existing credit facility with the Lender and executed a Release and Termination Note and Credit Agreement to release the Company from any future obligations under the Credit Agreement executed on December 21, 2010. In addition, the Company received the discharge of mortgage notification indicating the mortgage related to this credit agreement was satisfied and discharged. In connection with the release and termination agreement, the Company recorded amortization expense in the amount of $545,000 to write-off the remaining unamortized debt issuance costs.
	Under the Credit Agreement the Company had agreed to certain covenants customarily found in such agreements including, but not limited to, a covenant prohibiting the Company from entering into a merger or acquisition of the Company without the prior consent of the Lender if any advances remain outstanding and a covenant requiring the Company to maintain a certain loan to collateral ratio.
	The interest rate applicable to each promissory note was 14% per annum and interest payments were due on each March 31, June 30, September 30 and December 31 during the term of the Credit Agreement.
	In addition, as consideration for entering into the Credit Agreement, on December 21, 2010, the Company issued to the Lender a ten-year warrant to purchase certain shares of the Company’s common stock, at an exercise price of $0.01 per share (the “Warrant”). The Warrant was immediately exercisable for 881,331 shares of Common Stock (the “Initial Warrant Shares”) with the remaining shares of Common Stock representing 1% of the Fully Diluted Shares (as defined therein) as of the Conditional Warrant Exercise Date (as defined therein) (the “Conditional Warrant”) became exercisable on July 1, 2012 if the Company had not achieved certain milestones related to the Company’s product development or financial growth. The Warrant was accounted for as an equity instrument. The fair value of the Initial Warrant of $724,000 was recorded as debt issuance costs and amortized on a straight-line basis, which approximated the effective interest method, over the stated term of the Credit Agreement of five years. Amortization expense of $639,000 was recognized for the year ended December 31, 2012. In August of 2012, upon termination of the credit agreement, the unamortized portion of the initial warrant of $545,000 was recognized as interest expense.
	The Initial Warrant for 881,331 shares was exercised on September 28, 2012. On December 21, 2010, the fair value of the Conditional Warrant was not considered to be material. As of December 31, 2012, the Company executed a settlement agreement with Amzak Capital Management, LLC in connection with the Conditional Warrant and issued to Amzak on December 21, 2010 a ten-year warrant to purchase up to 427,713 shares of its common stock, with an exercise price of $0.55 per share. The warrants were exercised in full on February 8, 2013. The Company recorded the fair value of the Conditional Warrant of $209,000 as debt issuance costs which was included in interest expense in 2012.
	The Lender is a shareholder of the Company and participated in the private placement on December 8, 2010.

Note_8_Series_A_Convertible_Pr

Note 8 - Series A Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2013
Series A Preferred Stock [Member]	'
Note 8 - Series A Convertible Preferred Stock [Line Items]	'
Preferred Stock [Text Block]	'
	8.      Series A Convertible Preferred Stock
	On December 5, 2007, pursuant to a subscription agreement entered into with an accredited investor, the Company sold (i) 50 shares of Series A Convertible Preferred Stock with a liquidation preference of $10,000 per share, with each share of preferred stock, convertible into 10,000 shares of common stock of the Company, subject to customary adjustments; and (ii) a warrant to purchase 175,000 shares of common stock at an exercise price of $1.25 per share that expired on December 5, 2009, two years from issuance, for aggregate consideration of $500,000. A summary of significant terms is as follows:
	Dividends- Series A Convertible Preferred Stock holders are not entitled to a dividend unless the Company declares and pays a cash dividend on the Common Stock. In that event, the holders of shares of Series A Preferred Stock shall be entitled to share in such dividends on a pro rata basis, as if their shares had been converted into shares of Common Stock.
	Conversion- The Series A Convertible Preferred Stock is convertible, at the option of the holders, into shares of the Company’s common stock at a conversion price of $1.00 per share. Based on the original purchase price of $10,000 per share of preferred, each share of Series A Convertible Preferred Stock is convertible into 10,000 shares of common stock. The Series A Convertible Preferred Stock also contains an automatic conversion wherein the shares will automatically convert into common shares when the closing price of the Company’s common stock is $2.50 for ten (10) consecutive trading days.
	Liquidation preference- The liquidation preference is $10,000 per share for a total of $500,000.
	The Company has accounted for the Series A Convertible Preferred Stock in accordance with the provisions of ASC 815-10, “Accounting for derivative instruments and hedging activities,” and ASC 470-20, “Accounting for debt instruments with specific conversion features”. The Company has allocated the value received between the preferred stock and the related warrants. The allocated value for the preferred stock and the related warrants was approximately $475,000 and $25,000, respectively. In addition, the Company evaluated the shares and determined a beneficial conversion feature existed within this transaction, which totaled $55,000; the preferred stock was further discounted by this amount. The beneficial conversion amount related to the value of the preferred stock and the associated warrant was then accreted back to the preferred stock in accordance with the conversion provision, which allowed for 100% to be converted immediately. The accretion was reflected as an expense in 2007. The warrants have been classified as an equity instrument.
	The Company has a total of 1,000,000 of authorized shares of preferred stock par value $0.01, including a total of 100 authorized shares of Series A Convertible Preferred Stock.
	On September 5, 2013, at the option of the holder, all of the issued and outstanding shares of the Series A Convertible Preferred Stock, par value $0.01 per share, of the Company were converted into 500,000 shares of the Company’s common stock, at a conversion price of $1.00 per share.
Series C Preferred Stock [Member]	'
Note 8 - Series A Convertible Preferred Stock [Line Items]	'
Preferred Stock [Text Block]	'
	9.    Series C Convertible Preferred Stock – 2010 Offering
	On March 29, 2010, the Company completed a $1,550,000 private placement with certain investors, including investment funds affiliated with Signet Healthcare Partners, G.P. and Jane E. Hager (the “Series C Offering”). As part of the Series C Offering, the Company issued 1,550 shares of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock has a par value of $0.01 per share and the holders are entitled to quarterly dividends at an annual rate of 5%, when and if declared by the Board of Directors. Furthermore each share of Series C Convertible Preferred Stock is convertible into shares of common stock equal to (i) 1,000 plus any accrued and unpaid dividends, divided by (ii) $0.69 (the closing price of the Company’s common stock on the date of issuance of the Series C Convertible Preferred Stock).
	The Company has a total of 1,000,000 shares of authorized shares of preferred stock par value $0.01, including a total of 1,550 of the Series C Convertible Preferred Stock.
	On December 6, 2013, the Company recognized a deemed dividend as a component of net loss attributable to common stockholders for the fair value of the additional shares issued to the former preferred stockholders, 415,118 shares of common stock at the conversion date or $1,308,000. All of the issued and outstanding shares of the Series C Convertible Preferred Stock, par value $0.01, of the Company, as well as accrued dividends of $1,308,000 automatically converted into an aggregate of 2,661,494 shares of the Company’s common stock, par value $0.01 per share, in accordance with the terms and conditions set forth in the original Certificate of Designation of the Rights and Preferences of Series C Convertible Preferred Stock (the “Certificate of Designation”), which specified a $0.69 conversion ratio.
	Pursuant to the terms of the Certificate of Designation, the shares of Series C Preferred Stock automatically convert into shares of the Company’s Common Stock upon the date that the closing price of the Company’s Common Stock shall have exceeded three times the Closing Price on the Issuance Date for a period of twenty-five consecutive trading days immediately preceding such date. Accordingly, on December 6, 2013 all of the shares of Series C Convertible Preferred Stock automatically converted into shares of the Company’s Common Stock.

Note_10_Stock_Based_Compensati

Note 10 - Stock Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	10.     Stock Based Compensation
	The 1999 Director Stock Option Plan, as amended (the “Director Plan”), provides for the grant of stock options to non-employee directors of the Company at an exercise price equal to the fair market value per share on the date of the grant. An aggregate of 1,975,000 shares have been approved and authorized for issuance pursuant to this plan. A total of 2,179,798 options have been granted to non-employee directors through December 31, 2013 and 727,782 of those have been forfeited through December 31, 2013 and returned to the option pool. The options granted under the Director Plan vest in full one year after their respective grant dates and have a maximum term of ten years.
	The 1999 Stock Incentive Plan, as amended (“1999 Plan”), replaced all previously authorized employee stock option plans, and no additional options may be granted under those previous plans. Under the 1999 Plan, options or stock awards may be granted to all of the Company's employees, officers, directors, consultants and advisors to purchase a maximum of 3,200,000 shares of common stock. However, pursuant to the terms of the 1999 Plan, no awards may be granted after March 16, 2009. A total of 2,892,500 options, having a maximum term of ten years, have been granted at 100% of the fair market value of the Company's common stock at the date of grant. Options outstanding under the 1999 Plan are generally exercisable in cumulative increments over four years commencing one year from date of grant.
	On June 26, 2009, the Board of Directors adopted, and the Company’s stockholders subsequently approved by partial written consent, the IGI Laboratories, Inc. 2009 Equity Incentive Plan (the “2009 Plan”). The 2009 Plan became effective on July 29, 2009. The 2009 Plan allows the Company to continue to grant options and restricted stock, as under the 1999 Plan, but also authorizes the Board of Directors to grant a broad range of other equity-based awards, including stock appreciation rights, restricted stock units and performance awards. The 2009 Plan has been created, pursuant to and consistent with the Company’s current compensation philosophy, to assist the Company in attracting, retaining and rewarding designated employees, directors, consultants and other service providers of the Company and its subsidiaries and affiliates, in a manner that will be cost efficient to the Company from both an economic and financial accounting perspective. On April 12, 2010, the Board of Directors adopted, and the Company’s stockholders subsequently approved, an amendment and restatement of the 2009 Plan to increase the number of shares of Common Stock available for grant under such plan by adding 2,000,000 shares of Common Stock. The 2009 Plan, as amended on May 19, 2010, authorizes up to 4,000,000 shares of the Company’s common stock for issuance pursuant to the terms of the 2009 Plan. The maximum number of shares that may be subject to awards made to any individual in any single calendar year under the 2009 Plan is 1,000,000 shares. As of December 31, 2013, options to purchase 1,919,500 shares of common stock were outstanding under the 2009 Plan. As of December 31, 2013, 1,473,748 shares of restricted stock had been granted under the 2009 Plan and 230,420 of those have been forfeited through December 31, 2013 and returned to the pool.
	In summary, there are 2,643,500 options outstanding under the 1999 Plan, The Director Plan and the 2009 Plan, collectively as of December 31, 2013.
	Stock Options
	There are 1,323,000 options available for issusance under the 1999 Plan, the Director Plan, and the 2009 Plan collectively as of December 31, 2013.
	The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula that uses assumptions noted in the following table. Expected volatilities and risk-free interest rates are based upon the expected life of the grant.
	Assumptions		2013					2012
	Dividend yield			0		%			0	%
	Risk free interest rate			0.48		%			0.39	%
	Estimated volatility factor		36.90%	-	43.1	%			54.5	%
	Expected life (years)		3.2	–	3.3				3.2
	Estimated volatility was calculated using the historical volatility of the Company’s stock over the expected life of the options. The expected life of the options was estimated based on the Company’s historical data. The forfeiture rates are estimated based on historical employment/directorship termination experience. The risk free interest rate is based on U.S. Treasury yields for securities with terms approximating the terms of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuation.
	Stock option transactions in each of the past two years under the aforementioned plans in total were:
			Shares				Exercise				Weighted Average
							Price Per Share				Exercise Price
	January 1, 2012 shares issuable
	Under options			1,448,016			0.55	-	1.74			1.16
	Granted			1,551,000			1.02	-	1.18			1.05
	Exercised			(40,000	)			0.65				0.65
	Expired			(15,000	)			0.65				0.65
	Forfeited			(337,516	)		0.55	-	1.52			1.22
	December 31, 2012 shares issuable
	Under options			2,606,500			0.55	-	1.74			1.1
	Granted			247,000			1.04	-	3.03			1.35
	Exercised			(129,336	)		1.02	-	1.27			1.08
	Expired			-				-				-
	Forfeited			(80,664	)		1.1	-	1.74			1.3
	December 31, 2013 shares issuable
	Under options			2,643,500			0.55	-	3.03			1.12
	Exercisable options at:
	31-Dec-13			1,452,496							$	1.13
	31-Dec-12			951,001							$	1.19
	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2013:
					Options Outstanding									Options Exercisable
	Range of				Number of				Weighted			Weighted		Number of		Weighted
	Exercise Price				Options				Average			Average		Options		Average
									Remaining			Exercise				Exercise
									Life (Years)			Price				Price
	$0.55	to	$1.00			218,000				4.83		$	0.76		214,000	$	0.75
	1.01	to	2			2,418,000				7.9			1.14		1,238,496		1.19
	2.01	to	3.03			7,500				9.87			2.83		-		-
	$0.55	to	$3.03			2,643,500				7.65		$	1.12		1,452,496	$	1.13
	The following table summarizes information concerning outstanding and exercisable options as of December 31, 2012:
					Options Outstanding									Options Exercisable
	Range of				Number of				Weighted			Weighted		Number of		Weighted
	Exercise Price				Options				Average			Average		Options		Average
									Remaining			Exercise				Exercise
									Life (Years)			Price				Price
	$0.55	to	$1.00			218,000				5.83		$	0.76		212,000	$	0.75
	1.01	to	1.5			2,213,500				8.43			1.09		564,001		1.21
	1.51	to	1.74			175,000				8.01			1.68		175,000		1.68
	$0.55	to	$1.74			2,606,500				8.19		$	1.1		951,001	$	1.19
	The Company has recorded an aggregate of $206,500 and $156,000 related to its stock option based expenses in cost of sales and selling, general and administrative expenses on the accompanying Statement of Operations for the years ended December 31, 2013 and 2012, respectively.
	The aggregate intrinsic value of options outstanding was $5,109,925 at December 31, 2013 and $82,270 at December 31, 2012. The aggregate intrinsic value of the options exercisable was $2,789,901 at December 31, 2013 and $62,410 at December 31, 2012. The total intrinsic value of the options exercised during 2013 and 2012 was $254,779 and $15,600, respectively.
	A summary of non-vested options at December 31, 2013 and changes during the year ended December 31, 2013 is presented below:
			Options				Weighted AverageGrant Date Fair Value
	Non-vested options at January 1, 2013			1,655,499			$	0.32
	Granted			247,000				0.38
	Vested			(656,831	)			0.33
	Forfeited			(54,664	)			0.37
	Non-vested options at December 31, 2013			1,191,004			$	0.32
As of December 31, 2013, there was $280,000 of total unrecognized compensation cost related to non-vested share-based compensation arrangements under the Plan. The costs will be recognized through November 2016.
Restricted Stock
The Company periodically grants restricted stock awards to certain officers and other employees that typically vest one to three years from their grant date. On December 30, 2013, in accordance with the terms of the employment agreement between Jason Grenfell-Gardner, President and CEO, and the Company excecuted on July 30, 2012, a restricted stock award in the amount of 325,000 shares was granted to Jason Grenfell-Gardner, with one third of the shares of restricted stock vested on December 30, 2013, and the remaining two thirds of the shares of restricted stock vesting in equal amounts on July 30, 2014 and July 30, 2015. The Company recognized $329,400 and $222,000, respectively, of compensation expense during the years ended December 31, 2013 and 2012 related to restricted stock awards.  Stock compensation expense is recognized over the vesting period of the restricted stock.  At December 31, 2013, the Company had approximately $621,300 of total unrecognized compensation cost related to non-vested restricted stock, all of which will be recognized through December 2015.
		Number of				Weighted Average
		Restricted Stock				Exercise Price
Non-vested balance at January 1, 2012			626,000			$	0.71
Changes during the period:
Shares granted			109,748				1
Shares vested			(529,330	)			0.76
Shares forfeited			(177,084	)			0.7
Non-vested balance at January 1, 2013			29,334			$	1
Changes during the period:
Shares granted			325,000				2.86
Shares vested			(108,333	)			2.86
Shares forfeited			-
Non-vested balance at December 31, 2013			246,001			$	2.64

Note_11_Stock_Warrants

Note 11 - Stock Warrants	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	11.      Stock Warrants
	Stock Warrants as of December 31, 2013 and 2012 consisted of:
		2013					2012
		Warrants			Weighted		Warrants			Weighted
					Average					Average
					Exercise Price					Exercise Price
	Beginning balance		782,259		$	0.85		1,235,877		$	0.35
	Stock warrants granted		-					814,914			0.29
	Stock warrants expired		-					-
	Stock warrants exercised		(427,713	)		0.55		(1,268,532	)		0.01
	Ending balance		354,546		$	1.21		782,259		$	0.85
	In connection with the private placement of the Company’s Common Stock on December 8, 2010, the Company granted common stock warrants to purchase 338,182 and 16,364 shares, respectively, to each of its two placement agents for $1.21 per share which expire on December 8, 2015.
	In connection with the Credit Agreement with Amzak Capital Management, LLC as more fully described in Note 7, on December 10, 2010, the Company issued a ten-year warrant to purchase 881,331 shares of the Company’s Common Stock for $0.01 per share. The warrant was exercised in full on September 28, 2012.
	In connection with the private placement of the Company’s common stock in 2012, the Company granted common stock warrants to purchase 387,201 shares for $0.01 per share, which expire December 2022. The warrants were exercised in full on December 27, 2012.
	The Company executed as of December 31, 2012 a settlement agreement with Amzak Capital Management, LLC (“Amzak”) in connection with a common stock purchase warrant issued to Amzak on December 21, 2012 under which the Company issued a ten-year warrant to purchase up to 427,713 shares of the Company’s common stock, with an exercise price of $0.55 per share. The warrant was exercised in full on February 8, 2013. The amount of the fair value of the warrant issued was $209,000, and included as interest expense in 2012, as it related to the credit agreement which was terminated in August of 2012.

Note_12_Income_Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	12.      Income Taxes
	The Company’s current tax benefit was $197,000 and $184,000 for the year ended December 31, 2013 and 2012, respectively. The (benefit) from income taxes attributable to loss from continuing operations before (benefit) from income taxes for the years ended December 31, 2013 and 2012 is as follows:
		2013			2012
		(in thousands)
	Current tax expense (benefit):
	Federal	$	—		$	—
	State and local		(197	)		(184	)
	Total current tax expense (benefit)		(197	)		(184	)
	Deferred tax expense
	Federal		—			—
	State and local		—			—
	Total deferred tax expense		—			—
	Total expense (benefit) from income taxes	$	(197	)	$	(184	)
	The Company sold some of its New Jersey operating loss carry forwards under a program of the New Jersey Economic Development Authority (NJEDA) in exchange for net proceeds of $197,000 and $189,000 in 2013 and 2012 respectively. In order to realize these benefits, the Company must apply to the NJEDA each year and must meet various requirements for continued eligibility. In addition, the program must continue to be funded by the state of New Jersey, and there are limitations based on the level of participation by other companies. Since these specific sale transactions are subject to approval by the NJEDA, the Company recognizes the associated tax benefits in the financial statements as they are approved.
	The (benefit) from income taxes differed from the amount of income taxes determined by applying the applicable federal tax rate (34%) to pretax loss from continuing operations as a result of the following:
		2013			2012
		(in thousands)
	Statutory benefit	$	(95	)	$	(1,381	)
	Other non-deductible expenses		2			1
	Increase in federal valuation allowance		30			1,317
	Sale of New Jersey net operating loss carry forward		(197	)		(189	)
	Federal tax impact of state tax benefit, net		63			68
		$	(197	)	$	(184	)
	Deferred tax assets included in the Consolidated Balance Sheets as of December 31, 2013 and 2012 consisted of the following:
		2013			2012
		(in thousands)			(in thousands)
	Current Assets
	Allowance for doubtful accounts	$	6		$	6
	Inventory reserve		115			45
	Other		161			151
	Total Current Assets		282			202
	Long Term Assets (Liabilities)
	Property, plant and equipment		209			203
	Deferred royalty payments		5			10
	Tax operating loss carry forwards		10,672			11,101
	Tax credit carry forwards		217			225
	Non-employee stock options		685			625
	Other		(8	)		(8	)
	Total Long Term Assets (Liabilities)		11,780			12,156
	Gross Deferred Tax Asset (Liability)		12,062			12,358
	Less: valuation allowance		(12,062	)		(12,358	)
	Deferred taxes, net	$	—		$	—
	The Company evaluates the recoverability of its deferred tax assets based on its history of operating earnings, its plan to sell the benefit of certain state net operating loss carry forwards, its expectations for the future, and the expiration dates of the net operating loss carry forwards. The Company has concluded that it is more likely than not that it will be unable to realize the gross deferred tax assets in the immediate future and has established a valuation allowance for all such deferred tax assets. Accordingly, the Company has provided a valuation allowance of $12.1 million and $12.4 million for the years ended December 31, 2013 and 2012, respectively, on the deferred tax assets relating to these net operating loss carry forwards.
	Operating loss and tax credit carry forwards for tax reporting purposes as of December 31, 2013 were as follows:
		(in thousands)
	Federal:
	Operating losses (expiring through 2032)	$	31,308
	Research tax credits (expiring through 2025)		168
	Alternative minimum tax credits (available without expiration)		28
	State:
	Net operating losses - Tennessee (expiring in 2027)		425
	Alternative minimum assessment – New Jersey (available without expiration)		21
	Federal net operating loss carry forwards that expire through 2032 have significant components expiring in 2020 (21%), 2029 (11%), 2030 (11%), 2031 (9%) and 2032 (12%).
	The Company’s ability to use net operating loss carry forwards may be subject to substantial limitation in future periods under certain provisions of Section 382 of the Internal Revenue Code, which limit the utilization of net operating losses upon a more than 50% change in ownership of the Company’s stock that is held by 5% or greater stockholders. The Company examined the application of Section 382 with respect to an ownership change that took place during 2009 and 2010, as well as the possibility of such limitation having any material effect on the application of net operating loss carry forwards in the immediate future. The Company believes that it is likely that a change in ownership took place and that the net operating loss carry forwards will be limited.
	The Company complies with ASC 740-10-25 and there was no effect on the Company’s consolidated financial position and results of operations. Accordingly, there is no interest and penalties recorded on the balance sheet for such reserves. The Company is currently open to audit under the statute of limitations by the Internal Revenue Service and the appropriate state income taxing authorities for the tax years 2009 to 2012 due to the net loss carry forwards from those years.

Note_13_Lease_Commitments

Note 13 - Lease Commitments	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	13.      Lease Commitments
	The Company’s commitments and contingencies consisted of operating leases for warehouse space and equipment of $95,800 for 2014, $97,200 for 2015, $98,700 for 2016, $98,700 for 2017 and $34,200 for 2018. Rent expense was $121,700 and $66,900 for the years ended December 31, 2013 and 2012, respectively.

Note_14_Legal_and_US_Regulator

Note 14 - Legal and U.S. Regulatory Proceedings	12 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Legal Matters and Contingencies [Text Block]	'
	14.      Legal and U.S. Regulatory Proceedings
	On March 2, 2001, the Company became aware of environmental contamination resulting from an unknown heating oil leak at its former manufacturing facility. The Company immediately notified the New Jersey Department of Environmental Protection (NJ DEP) and the local authorities, and hired a contractor to assess the exposure and required clean up. The total estimated costs for the clean-up and remediation is $739,000, of which approximately $6,000 remains accrued as of December 31, 2013. Based on information provided to the Company from its environmental consultant and what is known to date, the Company believes the reserve is sufficient for the remaining remediation of the environmental contamination. There is a possibility, however, that the remediation costs may exceed the Company’s estimates.
	The restricted cash on the Consolidated Balance Sheet of $54,000 as of December 31, 2013 and 2012 represents a restricted escrow account set up on the requirement of the NJ DEP for the soil remediation work. These funds will be released to the Company upon the DEP approval when the remediation is completed.
	On December 19, 2013, we initiated a lawsuit in the United States District Court for the District of Delaware against Mallinckrodt LLC, Mallinckrodt, Inc. and Nuvo Research, Inc. seeking a declaration of non-infringement of United States Patent Nos. 8,217,078 and 8,546,450 so that we can bring our generic diclofenac sodium topical solution 1.5% to market at the earliest possible date under applicable statutory and FDA regulatory provisions.
	On January 10, 2014, Mallinckrodt filed an answer and counterclaim alleging that the Company infringes the patents at issue. On January 28, 2014, we filed a motion to dismiss Mallinckrodt's counterclaim and, on March 5, 2014, Mallinckrodt filed an opposition to such motion. The court has not yet rendered a decision. The Company believes the complaint has merit, and the Company intends to continue to pursue Mallinckrodt. Based on the early stage of this complaint and counterclaim, the Company is unable to predict the outcome.

Note_15_Employee_Benefits

Note 15 - Employee Benefits	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Other Postretirement Benefits Disclosure [Text Block]	'
	15.      Employee Benefits
	The Company has a 401(k) contribution plan, pursuant to which employees may elect to contribute to the plan, in whole percentages, up to 100% of compensation. Employees’ contributions are subject to a minimum contribution by participants of 1% of compensation and a maximum contribution of $17,500 for 2013 and $17,000 for 2012, plus a catch-up contribution of up to $5,500 for 2013 and 2012, if a participant qualifies. The Company matches 100% of the first 3% of compensation contributed by participants and 50% of the next 2% of compensation contributed by participants. The Company contribution is in the form of cash, which is vested immediately. The Company has recorded charges to expense related to this plan of approximately $93,000 and $71,000 in 2013 and 2012, respectively.

Note_17_2012_Private_Placement

Note 17 - 2012 Private Placement	12 Months Ended
	Dec. 31, 2013
Investments Schedule [Abstract]	'
Investment [Text Block]	'
	17.      2012 Private Placement
	On December 21, 2012, the Company, closed a $2,000,000 private placement (the “Offering”) with Amzak Capital Management, LLC (the “Investor”). Pursuant to the terms of a Securities Purchase Agreement entered into with the Investor (the “Purchase Agreement”) on December 20, 2012, the Company issued to the Investor (i) 1,965,740 shares of the Company common stock, held in treasury (the “Shares”), and (ii) a ten-year warrant to purchase up to an aggregate of 387,201 shares of the Company common stock, with an exercise price of $0.01 per share (the “Warrants”). The Warrants are exercisable immediately. The Company used the proceeds from this Offering to for general working capital as well as the acquisition of econozale nitrate cream 1% which was purchased on February 1, 2013.
	In connection with the Offering, the Company also entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of December 20, 2012, with the Investor, relating to the registration of the Shares, the Warrants and the shares of common stock issuable upon the exercise of the Warrants, issued in connection with the Offering (the “Registrable Shares”). The Registration Rights Agreement provides that the Company will file a “resale” registration statement (the “Initial Registration Statement”) covering all of the Registrable Shares within six months of the date of the Registration Rights Agreement and that such Initial Registration Statement shall be declared effective within nine months of the date of the Registration Rights Agreement, subject to certain limitations. Further, the Company has agreed to pay the Investor specified cash payments as partial liquidated damages in the event the Initial Registration Statement is not declared effective by the Securities and Exchange Commission (the “SEC”) within the specified timeframe. The Initial Registration Statement was filed with the SEC on May 9, 2013, within six months of the date of the Registration Rights Agreement and became effective on May 13, 2013, within nine months of the date of the Registration Rights Agreement.

Note_18_Asset_Purchase_Agreeme

Note 18 - Asset Purchase Agreement	12 Months Ended
	Dec. 31, 2013
Asset Purchase Agreement Disclosure [Abstract]	'
Asset Purchase Agreement Disclosure [Text Block]	'
	18.       Asset Purchase Agreement
	On February 1, 2013, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Prasco, LLC, an Ohio limited liability company (“Prasco”), pursuant to which the Company purchased from Prasco assets associated with econazole nitrate cream 1% (the “Product”), which is available in 15g, 30g, and 85g tubes has United States Food and Drug Administration approved indications for the treatment of tinea pedis, tinea cruris, and tinea corporis as well as the treatment of cutaneous candidiasis and tinea versicolor.
	In consideration for the purchase of the assets pursuant to the Purchase Agreement, the Company paid Prasco $1.4 million in cash and paid an additional aggregate of $400,000 upon the occurrence of the milestone events (the “Milestone Payment”). The Milestone Payment is secured by a first-priority security interest in the acquired assets under the Purchase Agreement. The transaction is accounted for as a purchase of the product and product rights, and as such the initial payment, milestone payment and related costs to acquire the asset are included as part of product acquisition costs totaling $1.8 million.  The Company capitalized and amortized the costs over fifteen years, the useful life of the acquired product and product rights.
	Under and subject to the terms and conditions of the Purchase Agreement, Prasco continued to distribute the Product during a six-month period following the closing of the Purchase Agreement, and the Company completed the technical transfer of the Product and begun manufacturing the Product under its own label during the third quarter of 2013. The Company’s product sales in the third quarter included sales of the product.
	In addition, the Purchase Agreement contains certain non-compete restrictions preventing Prasco from selling the Product in United States for a period of seven years.
	On October 23, 2013, the Company announced that it had received formal approval from the U.S. Food and Drug Administration (FDA) for the CBE-30 supplemental filing to approve the site transfer of the Econazole nitrate cream 1%, to the Company’s manufacturing facility in Buena, NJ.

Note_19_Subsequent_Event

Note 19 - Subsequent Event	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	19.       Subsequent Events
	On March 3, 2014, the Company submitted its ANDA in 2014 to the FDA, which brings the Company’s total number of ANDA submissions to fourteen.
	On March 12, 2014, the Company received its first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. Lidocaine hydrochloride USP 4% topical solution is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract.
	On March 25, 2014, the Board of Directors of the Company, at the recommendation of its Organization and Compensation Committee, resolved to award a cash bonus in the amount of $75,000 to its President and Chief Executive Officer, Jason Grenfell-Gardner. Mr. Grenfell-Gardner is also a director of the Company.
	On March 31, 2014, the Company filed a Form 8K disclosing that on March 25, 2014, Joyce Erony, a director and the chairperson of the IGI Laboratories, Inc.’s Board of Directors, advised us that she will not stand for re-election as a director at the Comapny's annual meeting to be held on May 27, 2014. Also included in the 8K, was the announcement that on March 28, 2014, Michael B. Hemric advised the Company that he will be resigning as director of the Company's Board of Directors effective April 1, 2014. We have begun the interview process to appoint new directors to the Company’s Board.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Business Description and Basis of Presentation [Text Block]	'
	Nature of the Business
	IGI Laboratories, Inc. is a Delaware corporation formed in 1977. On May 7, 2008, the stockholders of IGI, Inc. approved the name change of the Company from IGI, Inc. to IGI Laboratories, Inc. The Company’s office, laboratories and manufacturing facilities are located at 105 Lincoln Avenue, Buena, New Jersey. The Company is a developer, manufacturer, and marketer of topical formulations. The Company’s goal is to become a leader in the generic topical pharmaceutical market. In its own label, the Company sells generic topical pharmaceutical products that are bioequivalent to their brand name counterparts. The Company also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter (OTC), and cosmetic markets.
	Currently, we have two platforms for growth:
		■	Manufacturing, developing, and marketing a portfolio of generic pharmaceutical products in our own label in topical dosage forms; and,
		■	Increasing our current contract manufacturing and formulation services business.
	In addition, we will continue to explore ways to accelerate our growth through the creation of unique opportunities from the acquisition of additional intellectual property, and the expansion of the use of our existing intellectual property, including our licensed Novasome ® technology.
	To date, we have filed fourteen Abbreviated New Drug Applications, or ANDAs, with the United States Food and Drug Administration, or FDA for additional pharmaceutical products. We expect to continue to expand our presence in the generic topical pharmaceutical market through the filing of additional ANDAs with the FDA and the subsequent launch of products as these applications are approved. Our target is to file at least ten ANDAs in 2014 through our internal research and development program. On March 12, 2014, the Company received our first approval from the FDA for an ANDA. The FDA has approved IGI's application for lidocaine hydrochloride USP 4% topical solution. We will also seek to license or acquire further products, intellectual property, or ANDAs to expand our portfolio. On February 1, 2013, we acquired assets and intellectual property, including an ANDA, for econazole nitrate cream 1%, which we launched in September 2013.
	IGI also develops manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers as well as the OTC and cosmetic markets. These products are used in a wide range of applications from cosmetics and cosmeceuticals to the prescription treatment of conditions like dermatitis, psoriasis, and eczema.
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of IGI Laboratories, Inc. and its wholly owned and majority-owned subsidiaries. All inter-company accounts and transactions have been eliminated.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash Equivalents
	Cash equivalents consist of short-term investments, which have original maturities of 90 days or less.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of cash and cash equivalents, trade receivables, restricted cash, notes payable, accounts payable, capital leases and other accrued liabilities at December 31, 2013 approximate their fair value for all periods presented.
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	'
	Accounts Receivable and Allowance for Doubtful Accounts
	The Company extends credit to its contract services customers, based upon credit evaluations, in the normal course of business, primarily with 30-day terms. The Company does not require collateral from its customers. Bad debt provisions are provided for on the allowance method based on historical experience and management’s evaluation of outstanding accounts receivable. The Company reviews the allowance for doubtful accounts regularly, and past due balances are reviewed individually for collectability. The Company charges off uncollectible receivables against the allowance when the likelihood of collection is remote.
	The Company extends credit to wholesaler and distributor customers and national retail chain customers, based upon credit evaluations, in the normal course of business, primarily with 60-day terms. The Company maintains customer-related accruals and allowances that consist primarily of chargebacks, rebates, sales returns, shelf stock allowances, administrative fees and other incentive programs. Some of these adjustments relate specifically to the generic prescription pharmaceutical business. Typically, the aggregate gross-to-net adjustments related to these customers can exceed 50% of the gross sales through this distribution channel. Certain of these accruals and allowances are recorded in the balance sheet as current liabilities and others are recorded as a reduction in accounts receivable.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable.
	The Company maintains its cash in accounts with quality financial institutions. Although the Company currently believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to us, there is no assurance that those institutions will be able to continue to do so.
	In 2013, the Company had sales to three customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million, $2.2 million and $2.1 million, respectively, and aggregately represented 39% of total revenues. Accounts receivable related to the Company’s major customers comprised 11% of all accounts receivable as of December 31, 2013.
	In 2012, the Company had sales to two customers which individually accounted for more than 10% of the Company’s total revenue. These customers had sales of $2.8 million and $1.8 million, respectively, and aggregately represented 54% of total revenues. Accounts receivable related to the Company’s major customers comprised 59% of all accounts receivable as of December 31, 2012.
Inventory, Policy [Policy Text Block]	'
	Inventories
	Inventories are valued at the lower of cost, using the first-in, first-out (“FIFO”) method, or market. The company records an inventory reserve for losses associated with dated and expired raw materials. This reserve is based on management’s current knowledge with respect to inventory levels, planned production, and extension capabilities of materials on hand. Management does not believe the Company’s inventory is subject to significant risk of obsolescence in the near term. Reserve for obsolescence included in inventory at December 31, 2013 and 2012 were $0.2 million and $0.1 million respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	'
	Property, Plant and Equipment
	Depreciation and amortization of property, plant and equipment is provided for under the straight-line method over the assets’ estimated useful lives as follows:
			Useful Lives
			(years)
	Buildings and improvements		10	-	30
	Machinery and equipment		3	-	10
	Repair and maintenance costs are charged to operations as incurred while major improvements are capitalized. When assets are retired or disposed, the related cost and accumulated depreciation thereon are removed and any gains or losses are included in operating results.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	'
	Intangible Assets
	Intangible assets consist of the cost of an acquired product and product rights. Intangible assets are amortized over fifteen years (the asset’s estimated useful life).
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	'
	Long-Lived Assets
	In accordance with the provisions of ASC 360-10-55, the Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In performing such review for recoverability, the Company compares expected future cash flows of assets to the carrying value of the long-lived assets and related identifiable intangibles. If the expected future cash flows (undiscounted) are less than the carrying amount of such assets, the Company recognizes an impairment loss for the difference between the carrying value of the assets and their estimated fair value, with fair values being determined using projected discounted cash flows at the lowest level of cash flows identifiable in relation to the assets being reviewed. As of December 31, 2013, no impairments existed.
Loans and Leases Receivable, Nonaccrual Loan and Lease Status, Policy [Policy Text Block]	'
	Accrued Expenses
	Accrued expenses represent various obligations of the Company including certain operating expenses and taxes payable. For the fiscal year ended December 31, 2013, the largest component of accrued expenses was accrued royalties of $945,000, accrued payroll of $704,000, accrued wholesaler fees of $624,500 and accrued directors’ fees of $214,500. For the fiscal year ended December 31, 2012, the largest component of accrued expenses was accrued payroll of $256,700, accrued directors’ fees of $209,900 and accrued consulting fees of $60,000.
Revenue Recognition, Services, Licensing Fees [Policy Text Block]	'
	License Fee
	License fees are amortized on a straight-line basis over the life of the agreement (10 years).
Environmental Costs, Policy [Policy Text Block]	'
	Accounting for Environmental Costs
	Accruals for environmental remediation are recorded when it is probable a liability has been incurred and costs are reasonably estimable. The estimated liabilities are recorded at undiscounted amounts. Environmental insurance recoveries are included in the statement of operations in the year in which the issue is resolved through settlement or other appropriate legal process.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company records income taxes in accordance with ASC 740-10, “Accounting for Income Taxes,” under the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred income taxes are recognized for the tax consequences of temporary differences by applying enacted statutory tax rates applicable to future years to operating loss and tax credit carry forwards and differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities. The effect on deferred taxes of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded based on a determination of the ultimate realizability of future deferred tax assets. A valuation allowance equal to 100% of the net deferred tax assets has been recognized due to uncertainty regarding the future realization of these assets.
	The Company complies with the provisions of ASC 740-10-25 that clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements in accordance with ASC 740-10, “Accounting for Income Taxes,” and prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There were no unrecognized tax benefits as of the date of adoption. As such, there are no unrecognized tax benefits included in the balance sheet that would, if recognized, affect the effective tax rate.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, delivery has occurred or contractual services rendered, the sales price is fixed or determinable, and collection is reasonably assured in conformity with ASC 605, Revenue Recognition.
	The Company derives its revenues from three basic types of transactions: sales of its own generic pharmaceutical topical products, sales of manufactured product for its customers, and research and product development services performed for third parties.  Due to differences in the substance of these transaction types, the transactions require, and the Company utilizes, different revenue recognition policies for each.
	Product Sales: Product Sales includes IGI Product Sales and Contract Manufacturing Sales.
	IGI Product Sales: The Company records revenue from IGI product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery of products to the customer.
	Revenue and Provision for Sales Returns and Allowances
	As customary in the pharmaceutical industry, the Company’s gross product sales from IGI label products are subject to a variety of deductions in arriving at reported net product sales. When the Company recognizes revenue from the sale of products, an estimate of sales returns and allowances (“SRA”) is recorded, which reduces product sales. Accounts receivable and/or accrued expenses are also reduced and/or increased by the SRA amount. These adjustments include estimates for chargebacks, rebates, cash discounts and returns and other allowances. Currently these provisions are based on industry standards and current contract sales terms with direct and indirect customers. Over time, these provisions will be adjusted as estimates will be based on historical payment experience, historical relationship to revenues, estimated customer inventory levels and current contract sales terms with direct and indirect customers. The estimation process used to determine our SRA provision has been applied on a consistent basis and no material adjustments have been necessary to increase or decrease our reserves for SRA as a result of a significant change in underlying estimates. The Company will use a variety of methods to assess the adequacy of our SRA reserves to ensure that our financial statements are fairly stated. These will include periodic reviews of customer inventory data, customer contract programs and product pricing trends to analyze and validate the SRA reserves.
	The provision for chargebacks is our most significant sales allowance. A chargeback represents an amount payable in the future to a wholesaler for the difference between the invoice price paid to the Company by our wholesale customer for a particular product and the negotiated contract price that the wholesaler’s customer pays for that product. The Company’s chargeback provision and related reserve varies with changes in product mix, changes in customer pricing and changes to estimated wholesaler inventories. The provision for chargebacks also takes into account an estimate of the expected wholesaler sell-through levels to indirect customers at contract prices. The Company will validate the chargeback accrual quarterly through a review of the inventory reports obtained from our largest wholesale customers. This customer inventory information is used to verify the estimated liability for future chargeback claims based on historical chargeback and contract rates. These large wholesalers represent 90% - 95% of the Company’s chargeback payments. The Company continually monitors current pricing trends and wholesaler inventory levels to ensure the liability for future chargebacks is fairly stated.
	Net revenues and accounts receivable balances in the Company’s consolidated financial statements are presented net of SRA estimates. Certain SRA balances are included in accounts payable and accrued expenses.
	Gross-To-Net Sales Deductions
			Twelve Months Ended December 31,
			2013			2012
			(in thousands)			(in thousands)
	Gross IGI product sales		$	15,001		$	18
	Reduction to gross product sales:
	Chargebacks and billbacks			(6,050	)		-
	Sales discounts and other allowances			(1,593	)		(1	)
	Total reduction to gross product sales		$	(7,643	)	$	(1	)
	Net IGI product sales		$	7,358		$	17
	Accounts receivable are presented net of SRA balances of $1.9 million and $0 at December 31, 2013 and 2012, respectively. Accounts payable and accrued expenses include $0.6 million and $0 at December 31, 2013 and 2012, respectively, for certain fees related to services provided by the wholesalers. Wholesale fees of $0.9 million and $0 for the twelve month periods ended December 31 for 2013 and 2012, respectively, were included in cost of goods sold. In addition, in connection with three of the four products the Company currently manufactures, markets and distributes in its own label, in accordance with an agreement entered into in December of 2011, the Company is required to pay a royalty calculated based on net sales to one of its pharmaceutical partners. The royalty is calculated based on contracted terms of 40% of net sales for the three products which is to be paid quarterly to the pharmaceutical partner. In accordance with the agreement, net sales excludes fees related to services provided by the wholesalers. Accounts payable and accrued expenses include $0.9 million and $0 at December 31, 2013 and 2012, respectively, related to these royalties. Royalty expense of $2.6 million and $0 was included in cost of goods sold for the twelve months ended December 31 for 2013, and 2012 respectively. The Company includes significant estimates to arrive at net product sales arising from wholesaler chargebacks, Medicaid and Medicare rebates, allowances and other pricing and promotional programs.
	Contract Manufacturing Sales: The Company recognizes revenue when title transfers to its customers, which is generally upon shipment of products. These shipments are made in accordance with sales commitments and related sales orders entered into with customers either verbally or in written form. The revenues associated with these transactions, net of appropriate cash discounts, product returns and sales reserves, are recorded upon shipment of the products.
	Research and Development Income:  The Company establishes agreed upon product development agreements with its customers to perform product development services. Product development revenues are recognized in accordance with the product development agreement upon the completion of the phases of development and when the Company has no future performance obligations relating to that phase of development. Revenue recognition requires the Company to assess progress against contracted obligations to assure completion of each stage. These payments are generally non-refundable and are reported as deferred until they are recognizable as revenue. If no such arrangement exists, product development fees are recognized ratably over the entire period during which the services are performed.
	In making such assessments, judgments are required to evaluate contingencies such as potential variances in schedule and the costs, the impact of change orders, liability claims, contract disputes and achievement of contractual performance standards. Changes in total estimated contract cost and losses, if any, are recognized in the period they are determined. Billings on research and development contracts are typically based upon terms agreed upon by the Company and customer and are stated in the contracts themselves and do not always align with the revenues recognized by the Company.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation
	ASC 718-10 defines the fair-value-based method of accounting for stock-based employee compensation plans and transactions used by the Company to account for its issuances of equity instruments to record compensation cost for stock-based employee compensation plans at fair value as well as to acquire goods or services from non-employees. Transactions in which the Company issues stock-based compensation to employees, directors and advisors and for goods or services received from non-employees are accounted for based on the fair value of the equity instruments issued. The Company utilizes pricing models in determining the fair values of options and warrants issued as stock-based compensation. These pricing models utilize the market price of the Company’s common stock and the exercise price of the option or warrant, as well as time value and volatility factors underlying the positions. Stock-based compensation expense is recognized over the vesting period of the grant.
Debt, Policy [Policy Text Block]	'
	Debt Issuance Costs
	Expenses related to debt financing activities are capitalized and amortized on a straight-line basis, which approximates the effective interest method, over the term of the loan. On August 1, 2012, the Company paid-off its existing credit facility with Amzak Capital Management, LLC, and wrote-off the unamortized debt issuance costs to interest expense. The Company entered into a new loan agreement with Square 1 Bank, and in connection with this financing the Company incurred and recorded debt issuance costs in the amount of $114,000, which will be amortized over the remaining life of the loan, 42 months.
Research, Development, and Computer Software, Policy [Policy Text Block]	'
	Product Development and Research
	The Company's research and development costs are expensed as incurred.
Advertising Costs, Policy [Policy Text Block]	'
	Advertising Costs
	Advertising costs are expensed as incurred. Such expenses for the years ended December 31, 2013 and 2012 were $3,500 and $3,600, respectively.
Shipping and Handling Cost, Policy [Policy Text Block]	'
	Shipping and Handling Costs
	Costs related to shipping and handling is comprised of outbound freight and the associated labor. These costs are recorded in costs of sales.
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss per Common Share
	Basic net loss per share of common stock is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share of common stock is computed using the weighted average number of shares of common stock and potential dilutive common stock equivalents outstanding during the period. Potential dilutive common stock equivalents include shares issuable upon the exercise of options and warrants and the conversion of preferred stock. Due to the net loss for the years ended December 31, 2013 and 2012, the effect of the Company’s potential dilutive common stock equivalents was anti-dilutive for each year; as a result, the basic and diluted weighted average number of common shares outstanding and net loss per common share are the same. Potentially dilutive common stock equivalents, which were excluded from the net loss per share calculations due to their anti-dilutive effect amounted to 2,998,046 for 2013 and 6,445,628 for 2012.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include allowances for excess and obsolete inventories, allowances for doubtful accounts, provisions for income taxes and related deferred tax asset valuation allowances, stock based compensation and accruals for environmental cleanup and remediation costs. Actual results could differ from those estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When A Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-11”), which provides guidance on the presentation of unrecognized tax benefits when net operating loss carryforwards, similar tax losses, or tax credit carryforwards exist. The amendments in this update are effective for fiscal years (and interim periods within those years) beginning after December 15, 2013. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company does not expect ASU 2013-11 to have a material effect on its financial condition, results of operation or cash flows. This update will be effective for the Company for the year beginning January 1, 2014.

Note_1_Summary_of_Significant_1

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Property, Plant and Equipment, Estimated Useful Lives	'
		Useful Lives
		(years)
	Buildings and improvements	10	-	30
	Machinery and equipment	3	-	10
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	'
		Twelve Months Ended December 31,
		2013			2012
		(in thousands)			(in thousands)
	Gross IGI product sales	$	15,001		$	18
	Reduction to gross product sales:
	Chargebacks and billbacks		(6,050	)		-
	Sales discounts and other allowances		(1,593	)		(1	)
	Total reduction to gross product sales	$	(7,643	)	$	(1	)
	Net IGI product sales	$	7,358		$	17

Note_4_Inventories_Tables

Note 4 - Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		2013		2012
		(in thousands)		(in thousands)
	Raw materials	$	2,172	$	1,673
	Work in progress		271		26
	Finished goods		426		74
		$	2,869	$	1,773

Note_5_Property_Plant_and_Equi1

Note 5 - Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
		2013			2012
		(in thousands)			(in thousands)
	Land	$	257		$	257
	Building and improvements		3,599			3,552
	Machinery and equipment		3,375			3,120
	Construction in progress		128			123
			7,359			7,052
	Less accumulated depreciation and amortization		(4,736	)		(4,361	)
	Property, plant and equipment, net	$	2,623		$	2,691

Note_10_Stock_Based_Compensati1

Note 10 - Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Assumptions		2013					2012
	Dividend yield			0		%			0	%
	Risk free interest rate			0.48		%			0.39	%
	Estimated volatility factor		36.90%	-	43.1	%			54.5	%
	Expected life (years)		3.2	–	3.3				3.2
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
			Shares				Exercise				Weighted Average
							Price Per Share				Exercise Price
	January 1, 2012 shares issuable
	Under options			1,448,016			0.55	-	1.74			1.16
	Granted			1,551,000			1.02	-	1.18			1.05
	Exercised			(40,000	)			0.65				0.65
	Expired			(15,000	)			0.65				0.65
	Forfeited			(337,516	)		0.55	-	1.52			1.22
	December 31, 2012 shares issuable
	Under options			2,606,500			0.55	-	1.74			1.1
	Granted			247,000			1.04	-	3.03			1.35
	Exercised			(129,336	)		1.02	-	1.27			1.08
	Expired			-				-				-
	Forfeited			(80,664	)		1.1	-	1.74			1.3
	December 31, 2013 shares issuable
	Under options			2,643,500			0.55	-	3.03			1.12
	Exercisable options at:
	31-Dec-13			1,452,496							$	1.13
	31-Dec-12			951,001							$	1.19
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
					Options Outstanding									Options Exercisable
	Range of				Number of				Weighted			Weighted		Number of		Weighted
	Exercise Price				Options				Average			Average		Options		Average
									Remaining			Exercise				Exercise
									Life (Years)			Price				Price
	$0.55	to	$1.00			218,000				4.83		$	0.76		214,000	$	0.75
	1.01	to	2			2,418,000				7.9			1.14		1,238,496		1.19
	2.01	to	3.03			7,500				9.87			2.83		-		-
	$0.55	to	$3.03			2,643,500				7.65		$	1.12		1,452,496	$	1.13
					Options Outstanding									Options Exercisable
	Range of				Number of				Weighted			Weighted		Number of		Weighted
	Exercise Price				Options				Average			Average		Options		Average
									Remaining			Exercise				Exercise
									Life (Years)			Price				Price
	$0.55	to	$1.00			218,000				5.83		$	0.76		212,000	$	0.75
	1.01	to	1.5			2,213,500				8.43			1.09		564,001		1.21
	1.51	to	1.74			175,000				8.01			1.68		175,000		1.68
	$0.55	to	$1.74			2,606,500				8.19		$	1.1		951,001	$	1.19
Schedule of Nonvested Share Activity [Table Text Block]	'
			Options				Weighted AverageGrant Date Fair Value
	Non-vested options at January 1, 2013			1,655,499			$	0.32
	Granted			247,000				0.38
	Vested			(656,831	)			0.33
	Forfeited			(54,664	)			0.37
	Non-vested options at December 31, 2013			1,191,004			$	0.32
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
			Number of				Weighted Average
			Restricted Stock				Exercise Price
	Non-vested balance at January 1, 2012			626,000			$	0.71
	Changes during the period:
	Shares granted			109,748				1
	Shares vested			(529,330	)			0.76
	Shares forfeited			(177,084	)			0.7
	Non-vested balance at January 1, 2013			29,334			$	1
	Changes during the period:
	Shares granted			325,000				2.86
	Shares vested			(108,333	)			2.86
	Shares forfeited			-
	Non-vested balance at December 31, 2013			246,001			$	2.64

Note_11_Stock_Warrants_Tables

Note 11 - Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
		2013					2012
		Warrants			Weighted		Warrants			Weighted
					Average					Average
					Exercise Price					Exercise Price
	Beginning balance		782,259		$	0.85		1,235,877		$	0.35
	Stock warrants granted		-					814,914			0.29
	Stock warrants expired		-					-
	Stock warrants exercised		(427,713	)		0.55		(1,268,532	)		0.01
	Ending balance		354,546		$	1.21		782,259		$	0.85

Note_12_Income_Taxes_Tables

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		2013			2012
		(in thousands)
	Current tax expense (benefit):
	Federal	$	—		$	—
	State and local		(197	)		(184	)
	Total current tax expense (benefit)		(197	)		(184	)
	Deferred tax expense
	Federal		—			—
	State and local		—			—
	Total deferred tax expense		—			—
	Total expense (benefit) from income taxes	$	(197	)	$	(184	)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
		2013			2012
		(in thousands)
	Statutory benefit	$	(95	)	$	(1,381	)
	Other non-deductible expenses		2			1
	Increase in federal valuation allowance		30			1,317
	Sale of New Jersey net operating loss carry forward		(197	)		(189	)
	Federal tax impact of state tax benefit, net		63			68
		$	(197	)	$	(184	)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
		2013			2012
		(in thousands)			(in thousands)
	Current Assets
	Allowance for doubtful accounts	$	6		$	6
	Inventory reserve		115			45
	Other		161			151
	Total Current Assets		282			202
	Long Term Assets (Liabilities)
	Property, plant and equipment		209			203
	Deferred royalty payments		5			10
	Tax operating loss carry forwards		10,672			11,101
	Tax credit carry forwards		217			225
	Non-employee stock options		685			625
	Other		(8	)		(8	)
	Total Long Term Assets (Liabilities)		11,780			12,156
	Gross Deferred Tax Asset (Liability)		12,062			12,358
	Less: valuation allowance		(12,062	)		(12,358	)
	Deferred taxes, net	$	—		$	—
Summary of Operating Loss Carryforwards [Table Text Block]	'
		(in thousands)
	Federal:
	Operating losses (expiring through 2032)	$	31,308
	Research tax credits (expiring through 2025)		168
	Alternative minimum tax credits (available without expiration)		28
	State:
	Net operating losses - Tennessee (expiring in 2027)		425
	Alternative minimum assessment – New Jersey (available without expiration)		21

Note_1_Summary_of_Significant_2

Note 1 - Summary of Significant Accounting Policies (Details) (USD $)	0 Months Ended	12 Months Ended
	Feb. 02, 2013	Dec. 31, 2013	Dec. 31, 2012
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Accounts Receivable and Allowance for Doubtful Accounts Gross Net Adjustment Threshold	'	50.00%	'
Concentration Risk, Percentage	'	10.00%	'
Percent of Revenue	'	39.00%	54.00%
Percentage of Accounts Receivable	'	11.00%	59.00%
Inventory Valuation Reserves	'	$200,000	$100,000
Finite-Lived Intangible Asset, Useful Life	'15 years	'15 years	'
Accrued Royalties	'	945,000	'
Accrued Salaries	'	704,000	256,700
Accounts Payable and Accrued Liabilities	'	600,000	0
WholeSale Fees	'	900,000	0
Royalty Expense	'	2,600,000	0
Debt Issuance Cost	'	114,000	209,000
Number of Months	'	'42	'
Advertising Expense	'	3,500	3,600
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in Shares)	'	2,998,046	6,445,628
Wholesaler and Distrubtor Customers (Member)	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Credit Extensions, to Customers, Days	'	'60	'
Net of SRA Balance [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Accounts Receivable, Net	'	1,900,000	0
Customer Three [Member] | Sales Revenue, Product Line [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Revenue, Net	'	2,100,000	'
Customer One [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Revenue, Net	'	'	2,800,000
Customer Two [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Revenue, Net	'	'	1,800,000
Consulting Fees (Member)	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Accrued Professional Fees	'	624,500	60,000
Directors' fees (Member)	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Accrued Professional Fees	'	214,500	209,900
Royalty [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Accounts Payable and Accrued Liabilities	'	900,000	0
Customer One [Member] | Sales Revenue, Product Line [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Revenue, Net	'	2,800,000	'
Customer Two [Member] | Sales Revenue, Product Line [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Revenue, Net	'	$2,200,000	'
Sales Revenue, Product Line [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Number of Customers	'	3	'
Concentration Risk, Percentage	'	'	10.00%
Licensing Agreements [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'10 years	'
Minimum [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Whole Saler Percent of Chargebacks	'	90.00%	'
Maximum [Member]	'	'	'
Note 1 - Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'
Whole Saler Percent of Chargebacks	'	95.00%	'

Note_1_Summary_of_Significant_3

Note 1 - Summary of Significant Accounting Policies (Details) - Depreciation of Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2013
Building and Building Improvements [Member] | Minimum [Member]	'
Note 1 - Summary of Significant Accounting Policies (Details) - Depreciation of Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment	'10 years
Building and Building Improvements [Member] | Maximum [Member]	'
Note 1 - Summary of Significant Accounting Policies (Details) - Depreciation of Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment	'30 years
Machinery and Equipment [Member] | Minimum [Member]	'
Note 1 - Summary of Significant Accounting Policies (Details) - Depreciation of Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment	'3 years
Machinery and Equipment [Member] | Maximum [Member]	'
Note 1 - Summary of Significant Accounting Policies (Details) - Depreciation of Property, Plant and Equipment [Line Items]	'
Property, Plant and Equipment	'10 years

Note_1_Summary_of_Significant_4

Note 1 - Summary of Significant Accounting Policies (Details) - Net revenues and accounts receivable balances iThe Company's consolidated financial statements are presented net of SRA estimates (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Gross IGI product sales	$15,001	$18
Reduction to gross product sales:	'	'
Chargebacks and billbacks	-6,050	'
Sales discounts and other allowances	-1,593	-1
Total reduction to gross product sales	-7,643	-1
Net IGI product sales	16,981	6,545
Gross Net Adjustments [Member]	'	'
Reduction to gross product sales:	'	'
Net IGI product sales	$7,358	$17

Note_2_Liquidity_Details

Note 2 - Liquidity (Details) (USD $)	1 Months Ended	12 Months Ended
	Dec. 21, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2009	Aug. 31, 2012	Dec. 31, 2011	Dec. 21, 2010
Accounting Policies [Abstract]	'	'	'	'	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	'	$2,101,000	$2,536,000	'	'	'	$2,914,000	'
Line of Credit Facility, Remaining Borrowing Capacity	'	2,000,000	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	5,000,000	'	'	'	3,000,000	'	3,000,000
Net Income (Loss) Available to Common Stockholders, Basic	'	-1,392,000	-3,927,000	'	'	'	'	'
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	'	-84,000	-3,927,000	'	'	'	'	'
Working Capital	'	5,337,000	'	'	'	'	'	'
Proceeds from Issuance of Private Placement	2,000,000	'	2,000,000	7,213,000	5,304,000	'	'	'
Line of Credit Facility, Amount Outstanding	'	$3,000,000	'	'	'	'	'	'

Note_3_License_Fee_Details

Note 3 - License Fee (Details) (USD $)	0 Months Ended	12 Months Ended		12 Months Ended
	Feb. 02, 2013	Dec. 31, 2013	Dec. 12, 2005	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
				Licensing Agreements [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]	Licensing Agreements [Member]
Note 3 - License Fee (Details) [Line Items]	'	'	'	'	'	'	'
undefined	'	'	'10 years	'	'	'	'
Finite-Lived License Agreements, Gross	'	'	$1,000,000	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'15 years	'15 years	'	'	'	'10 years	'
Amortization	'	'	'	$100,000	$100,000	$100,000	$100,000

Note_4_Inventories_Details_Inv

Note 4 - Inventories (Details) - Inventories (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$2,172	$1,673
Work in progress	271	26
Finished goods	426	74
	$2,869	$1,773

Note_5_Property_Plant_and_Equi2

Note 5 - Property, Plant and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]	'	'
Depreciation	$375,000	$357,000

Note_5_Property_Plant_and_Equi3

Note 5 - Property, Plant and Equipment (Details) - Property, Plant and Equipment (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property Plant and Equipment	$7,359	$7,052
Less accumulated depreciation and amortization	-4,736	-4,361
Property, plant and equipment, net	2,623	2,691
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and Equipment	257	257
Building and Building Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and Equipment	3,599	3,552
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and Equipment	3,375	3,120
Construction in Progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property Plant and Equipment	$128	$123

Note_6_Note_Payable_Details

Note 6 - Note Payable (Details) (USD $)	0 Months Ended		1 Months Ended		12 Months Ended
	Aug. 02, 2013	Feb. 05, 2013	Jul. 26, 2013	Aug. 31, 2012	Dec. 31, 2013	Dec. 21, 2010
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Proceeds from Lines of Credit (in Dollars)	$1,000,000	$1,000,000	'	$1,000,000	'	'
Line of Credit Facility, Amount Outstanding (in Dollars)	'	'	'	'	3,000,000	'
Line of Credit Facility, Interest Rate During Period	'	'	8.65%	'	'	'
Debt Instrument, Payment Terms	'	'	'	'	'42	'
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)	'	'	'	3,000,000	5,000,000	3,000,000
Above Prime Rate [Member] | Formula Revolving Line (Member)	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Debt Instrument, Basis Spread on Variable Rate	'	'	4.90%	'	1.90%	'
trailing 3 month basis (Member)	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Covenant Terms	'	'	'	'	'three	'
Company Remains in Compliance Through December 2013 [Member] | Original Aggregate Borrowing [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)	'	'	3,000,000	'	'	'
Company Remains in Compliance Through December 2013 [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)	'	'	5,000,000	'	'	'
Formula Revolving Line (Member) | Above Prime Rate [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Debt Instrument, Basis Spread on Variable Rate	'	'	'	'	2.40%	'
Formula Revolving Line (Member)	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Debt Instrument, Basis Spread on Variable Rate	'	'	5.15%	'	2.15%	'
Line of Credit Facility, Interest Rate During Period	'	'	8.90%	'	5.65%	'
Non-Formula Revolving Line (Member)	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Interest Rate During Period	'	'	'	'	6.15%	'
Non-Formula Revolving Line (Member) | Maximum [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Interest Rate During Period	'	'	'	'	5.90%	'
Term of Line of Credit (Member)	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Line of Credit Facility, Covenant Terms	'	'	'	'	'one	'
Maximum [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Liquidity Ratio	'	'	1	'	1.25	'
Minimum [Member]	'	'	'	'	'	'
Note 6 - Note Payable (Details) [Line Items]	'	'	'	'	'	'
Liquidity Ratio	'	'	0.9	'	1	'

Note_7_Note_Payable_Related_Pa1

Note 7 - Note Payable - Related Party (Details) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

Aug. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 21, 2012

Sep. 28, 2012

Dec. 31, 2011

Dec. 21, 2010

Dec. 05, 2007

Dec. 12, 2005

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2010

Dec. 10, 2010

Jul. 31, 2012

Dec. 31, 2010

Jul. 31, 2012

Dec. 31, 2010

Dec. 31, 2010

Terms of Warrant (Member)

Warrant Issued in Connection with Credit Agreement (Member)

Warrant Issued in Connection with Credit Agreement (Member)

Warrant Issued in Connection with Credit Agreement (Member)

Initial Warrant Shares (Member)

Initial Warrant Shares (Member)

Conditional Warrant Shares (Member)

In Connection with Common Stock Purchase (Member)

Amzak Capital Management LLC [Member]

Note 7 - Note Payable - Related Party (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

$3,000,000

$5,000,000

'

'

'

'

$3,000,000

'

'

'

'

'

'

'

'

'

'

'

Amortization of Deferred Charges

545,000

'

639,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

14.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

undefined

'

'

'

'

'

'

'

'

'10 years

'10 years

'10 years

'10 years

'10 years

'5 years

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

1.21

0.85

0.01

'

0.35

'

1.25

'

'

0.01

0.01

0.01

'

'

'

0.55

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

354,546

782,259

387,201

881,331

1,235,877

'

175,000

'

'

387,201

'

881,331

'

881,331

'

'

427,713

Percent of Fully Diluted Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

Warrants and Rights Outstanding

'

'

'

'

'

'

'

25,000

'

'

'

'

'

724,000

'

'

'

'

Interest Expense

545,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Issuance Cost

'

$114,000

$209,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_8_Series_A_Convertible_Pr1

Note 8 - Series A Convertible Preferred Stock (Details) (USD $)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Dec. 06, 2013

Dec. 05, 2007

Dec. 21, 2012

Dec. 31, 2012

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2013

Sep. 28, 2012

Dec. 31, 2011

Dec. 05, 2007

Dec. 31, 2013

Sep. 05, 2013

Dec. 31, 2012

Dec. 05, 2007

Mar. 29, 2010

Dec. 06, 2013

Mar. 29, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 05, 2007

Common Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series C Offering (Member)

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

Subscription Agreement (Member)

Note 8 - Series A Convertible Preferred Stock (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of Stock, Number of Shares Issued in Transaction (in Shares)

'

50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference Per Share

'

$10,000

'

'

'

'

'

'

'

'

$0

'

$500,000

'

'

'

'

$0

$1,764,240

$10,000

Convertible Preferred Stock, Shares Issued upon Conversion (in Shares)

'

10,000

'

'

'

'

'

'

'

'

'

500,000

'

10,000

'

415,118

1,000

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

175,000

387,201

782,259

'

'

354,546

881,331

1,235,877

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

'

1.25

0.01

0.85

'

'

1.21

'

0.35

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Upon Conversion, Aggregate Consideration (in Dollars)

'

$500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Redemption Price Per Share

'

$1

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

Preferred Stock, Par or Stated Value Per Share

'

'

'

$0.01

'

'

'

'

'

'

$0.01

$0.01

$0.01

$10,000

'

$0.01

$0.01

$0.01

$0.01

'

Share Price

'

'

'

'

'

'

'

'

'

$2.50

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Terms of Conversion

'twenty-five

'ten

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Liquidation Preference, Value (in Dollars)

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Value, Issued (in Dollars)

'

475,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock, Beneficial Conversion Feature (in Dollars)

'

55,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shares Authorized (in Shares)

'

'

'

1,000,000

'

'

'

'

'

'

100

'

100

'

'

'

'

1,550

1,550

'

Proceeds from Issuance of Private Placement (in Dollars)

'

'

2,000,000

2,000,000

7,213,000

5,304,000

'

'

'

'

'

'

'

'

1,550,000

'

'

'

'

'

Stock Issued During Period, Shares, New Issues (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,550

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.00%

'

'

'

Common Stock, Par or Stated Value Per Share

$0.01

'

'

$0.01

'

'

$0.01

'

'

'

'

'

'

'

'

'

$0.69

'

'

'

Preferred Stock, Redemption Amount (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,308,000

'

'

'

'

Preferred Stock and Accrued Dividends on Stock Converted (in Shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,661,494

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.69

'

'

'

'

Note_10_Stock_Based_Compensati2

Note 10 - Stock Based Compensation (Details) (USD $)

12 Months Ended

132 Months Ended

12 Months Ended

12 Months Ended

132 Months Ended

3 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2009

Dec. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2009

17-May-09

Apr. 12, 2010

Dec. 31, 2013

Dec. 31, 2010

19-May-10

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Cost of Sales,Selling,General and Administrative Expense [Member]

Cost of Sales,Selling,General and Administrative Expense [Member]

Nineteen Ninety Nine Director Stock Options [Member]

Nineteen Ninety Nine Director Stock Options [Member]

Nineteen Ninety Nine Director Stock Options [Member]

Director Stock Option Plan - 1999 (Member)

Nineteen Ninety Nine Stock Incentive Plan [Member]

Nineteen Ninety Nine Stock Incentive Plan [Member]

Nineteen Ninety Nine Stock Incentive Plan [Member]

Two Thousand Nine Plan [Member]

Two Thousand Nine Plan [Member]

Two Thousand Nine Plan [Member]

Two Thousand Nine Plan [Member]

Plan 2009 (Member)

Plan 1999 [Member]

The Director Plan [Member]

1999 Plan, 2009 Plan and Director Plan [Member]

President and Chief Executive Officer (Member)

Minimum [Member]

Maximum [Member]

Minimum [Member]

Note 10 - Stock Based Compensation (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

1,975,000

'

'

'

'

3,200,000

'

'

1,000,000

4,000,000

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

247,000

1,551,000

'

'

'

'

'

'

'

'

2,179,798

'

'

'

2,892,500

'

'

'

'

'

'

1,473,748

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

80,664

337,516

'

'

'

'

'

'

'

'

'

'

'

727,782

'

'

'

'

'

'

'

230,420

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'1 year

'3 years

'

'

'

'

'1 year

'

'

'4 years

'

'

'

'

'

'

'

'

'

Award Term

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

Percent FMV Common Stock Options Granted

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period from Date of Grant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

2,643,500

1,448,016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,919,500

'

'

2,643,500

2,643,500

2,643,500

'

Common Stock, Capital Shares Reserved for Future Issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,323,000

Allocated Share-based Compensation Expense (in Dollars)

'

'

'

'

'

'

'

'

$206,500

$156,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

5,109,925

82,270

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

2,789,901

62,410

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

254,779

15,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

280,000

'

'

'

621,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

108,333

529,330

'

325,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation (in Dollars)

$536,000

$378,000

'

'

$329,400

$222,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_10_Stock_Based_Compensati3

Note 10 - Stock Based Compensation (Details) - Fair Value Assumptions of Option Awards	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Stock Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'	'
Dividend yield	0.00%	0.00%
Risk free interest rate	0.48%	0.39%
Estimated volatility factor	'	54.50%
Expected life (years)	'	'3 years 73 days
Minimum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'	'
Estimated volatility factor	36.90%	'
Expected life (years)	'3 years 73 days	'
Maximum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Fair Value Assumptions of Option Awards [Line Items]	'	'
Estimated volatility factor	43.10%	'
Expected life (years)	'3 years 109 days	'

Note_10_Stock_Based_Compensati4

Note 10 - Stock Based Compensation (Details) - Option Activity (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Shares	2,643,500	1,448,016
Weighted Average Exercise Price	$1.12	$1.16
Shares	1,452,496	951,001
Weighted Average Exercise Price	$1.13	$1.19
Shares	247,000	1,551,000
Weighted Average Exercise Price	$1.35	$1.05
Shares	-129,336	-40,000
Exercise Price Per Share	'	'.65
Weighted Average Exercise Price	$1.08	$0.65
Shares	'	-15,000
Exercise Price Per Share	'	'.65
Weighted Average Exercise Price	'	$0.65
Shares	-80,664	-337,516
Weighted Average Exercise Price	$1.30	$1.22
Total Shares Issuable under option plans (Member)	'	'
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Shares	'	2,606,500
Weighted Average Exercise Price	'	$1.10
Total Shares Issuable under option plans (Member) | Minimum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Exercise Price Per Share	'	'.55
Total Shares Issuable under option plans (Member) | Maximum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Exercise Price Per Share	'	'1.74
Minimum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Exercise Price Per Share	'.55	'.55
Exercise Price Per Share	'1.04	'1.02
Exercise Price Per Share	'1.02	'
Exercise Price Per Share	'1.10	'.55
Maximum [Member]	'	'
Note 10 - Stock Based Compensation (Details) - Option Activity [Line Items]	'	'
Exercise Price Per Share	'3.03	'1.74
Exercise Price Per Share	'3.03	'1.18
Exercise Price Per Share	'1.27	'
Exercise Price Per Share	'1.74	'1.52

Note_10_Stock_Based_Compensati5

Note 10 - Stock Based Compensation (Details) - Options Outstanding and Exercisable (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Weighted Average Exercise Price	$1.12	$1.16
Range $0.55 - $1.00 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	218,000	218,000
Options Outstanding - Weighted Average Remaining Life (Years)	'4 years 302 days	'5 years 302 days
Options Outstanding - Weighted Average Exercise Price	$0.76	$0.76
Range $0.55 - $1.00 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	214,000	212,000
Options Exercisable - Weighted Average Exercise Price	$0.75	$0.75
Range $0.55 - $1.00 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$0.55	$0.55
Range $0.55 - $1.00 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$1	$1
Range $1.01 - $ 2.00 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	2,418,000	'
Options Outstanding - Weighted Average Remaining Life (Years)	'7 years 328 days	'
Options Outstanding - Weighted Average Exercise Price	$1.14	'
Range $1.01 - $ 2.00 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	1,238,496	'
Options Exercisable - Weighted Average Exercise Price	$1.19	'
Range $1.01 - $ 2.00 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$1.01	'
Range $1.01 - $ 2.00 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$2	'
Range $2.01 - $3.03 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	7,500	'
Options Outstanding - Weighted Average Remaining Life (Years)	'9 years 317 days	'
Options Outstanding - Weighted Average Exercise Price	$2.83	'
Range $2.01 - $3.03 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$2.01	'
Range $2.01 - $3.03 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$3.03	'
Range $0.55 - $ 3.03 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	2,643,500	'
Options Outstanding - Weighted Average Remaining Life (Years)	'7 years 237 days	'
Options Outstanding - Weighted Average Exercise Price	$1.12	'
Range $0.55 - $ 3.03 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	1,452,496	'
Options Exercisable - Weighted Average Exercise Price	$1.13	'
Range $0.55 - $ 3.03 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$0.55	'
Range $0.55 - $ 3.03 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	$3.03	'
Range $1.01 - $ 1.50 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	'	2,213,500
Options Outstanding - Weighted Average Remaining Life (Years)	'	'8 years 156 days
Options Outstanding - Weighted Average Exercise Price	'	$1.09
Range $1.01 - $ 1.50 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	'	564,001
Options Exercisable - Weighted Average Exercise Price	'	$1.21
Range $1.01 - $ 1.50 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$1.01
Range $1.01 - $ 1.50 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$1.50
Range $ 1.51 - $ 1.74 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	'	175,000
Options Outstanding - Weighted Average Remaining Life (Years)	'	'8 years 3 days
Options Outstanding - Weighted Average Exercise Price	'	$1.68
Range $ 1.51 - $ 1.74 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	'	175,000
Options Exercisable - Weighted Average Exercise Price	'	$1.68
Range $ 1.51 - $ 1.74 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$1.51
Range $ 1.51 - $ 1.74 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$1.74
Range $0.55 - $1.74 [Member] | Options Outstanding [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding - Number of Options (in Shares)	'	2,606,500
Options Outstanding - Weighted Average Remaining Life (Years)	'	'8 years 69 days
Options Outstanding - Weighted Average Exercise Price	'	$1.10
Range $0.55 - $1.74 [Member] | Options Exercisable [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Exercisable - Number of Options (in Shares)	'	951,001
Options Exercisable - Weighted Average Exercise Price	'	$1.19
Range $0.55 - $1.74 [Member] | Minimum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$0.55
Range $0.55 - $1.74 [Member] | Maximum [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price	'	$1.74

Note_10_Stock_Based_Compensati6

Note 10 - Stock Based Compensation (Details) - Summary of Non Vesterd Options (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Note 10 - Stock Based Compensation (Details) - Summary of Non Vesterd Options [Line Items]	'	'	'
Non-vested options at January 1, 2013	$2.64	$1	$0.71
Granted	247,000	1,551,000	'
Vested	$2.86	$0.76	'
Forfeited	-80,664	-337,516	'
Non-vested options at December 31, 2013	$2.64	$1	$0.71
Non-Vested [Member]	'	'	'
Note 10 - Stock Based Compensation (Details) - Summary of Non Vesterd Options [Line Items]	'	'	'
Non-vested options at January 1, 2013	1,655,499	'	'
Non-vested options at January 1, 2013	$0.32	'	'
Granted	247,000	'	'
Granted	$0.38	'	'
Vested	-656,831	'	'
Vested	$0.33	'	'
Forfeited	-54,664	'	'
Forfeited	$0.37	'	'
Non-vested options at December 31, 2013	1,191,004	'	'
Non-vested options at December 31, 2013	$0.32	'	'

Note_10_Stock_Based_Compensati7

Note 10 - Stock Based Compensation (Details) - Restricted Stock Awards (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Restricted Stock Awards [Abstract]	'	'
Non-vested balance at	29,334	626,000
Non-vested balance at	$1	$0.71
Changes during the period:	'	'
Shares Granted	325,000	109,748
Shares Granted - Weighted Average Exercise Price	$2.86	$1
Shares Vested	-108,333	-529,330
Shares Vested - Weighted Average Exercise Price	$2.86	$0.76
Shares Forfeited	'	-177,084
Shares Forfeited - Weighted Average Exercise Price	'	$0.70
Non-vested balance at December 31, 2013	246,001	29,334
Non-vested balance at December 31, 2013	$2.64	$1

Note_11_Stock_Warrants_Details

Note 11 - Stock Warrants (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 21, 2012

Sep. 28, 2012

Dec. 31, 2011

Dec. 05, 2007

Dec. 12, 2005

Dec. 31, 2012

Dec. 31, 2010

Dec. 10, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 08, 2010

Dec. 08, 2010

Dec. 08, 2010

Warrant Issued in Connection with Credit Agreement (Member)

Warrant Issued in Connection with Credit Agreement (Member)

Warrant Issued in Connection with Credit Agreement (Member)

Warrant Purchase Limit (Member)

Value of Warrants Outstanding (Member)

Warrant Issued in Connection with Private Placement Offering (Member)

First Placement Agent (Member)

Second Placement Agent (Member)

Note 11 - Stock Warrants (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

354,546

782,259

387,201

881,331

1,235,877

175,000

'

387,201

'

881,331

427,713

'

'

338,182

16,364

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)

1.21

0.85

0.01

'

0.35

1.25

'

0.01

0.01

0.01

0.55

'

1.21

'

'

undefined

'

'

'

'

'

'

'10 years

'10 years

'10 years

'10 years

'

'

'

'

'

Warrants and Rights Outstanding (in Dollars)

'

'

'

'

'

$25,000

'

'

'

'

'

$209,000

'

'

'

Note_11_Stock_Warrants_Details1

Note 11 - Stock Warrants (Details) - Stock Warrants (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 21, 2012	Sep. 28, 2012	Dec. 05, 2007
Stock Warrants [Abstract]	'	'	'	'	'
Beginning balance	782,259	1,235,877	387,201	881,331	175,000
Beginning balance (in Dollars per Item)	0.85	0.35	0.01	'	1.25
Stock warrants granted	'	814,914	'	'	'
Stock warrants granted (in Dollars per share)	'	$0.29	'	'	'
Stock warrants exercised	-427,713	-1,268,532	'	'	'
Stock warrants exercised (in Dollars per share)	$0.55	$0.01	'	'	'
Ending balance	354,546	782,259	387,201	881,331	175,000
Ending balance (in Dollars per Item)	1.21	0.85	0.01	'	1.25

Note_12_Income_Taxes_Details

Note 12 - Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Income Taxes (Details) [Line Items]	'	'
Income Tax Expense (Benefit) (in Dollars)	($197,000)	($184,000)
Proceeds from Sale of Operating Loss Carryforwards (in Dollars)	197,000	189,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	'
Deferred Tax Assets, Valuation Allowance (in Dollars)	$12,100,000	$12,400,000
Change in Ownership Percent	50.00%	'
Stockholder Ownership	5.00%	'
Expiring in 2020 [Member]	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carry Forward Expiration Percent	21.00%	'
Expiring in 2029 [Member]	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carry Forward Expiration Percent	11.00%	'
Expiring in 2030 [Member]	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carry Forward Expiration Percent	11.00%	'
Expiring in 2031 [Member]	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carry Forward Expiration Percent	9.00%	'
Expiring in 2032 [Member]	'	'
Note 12 - Income Taxes (Details) [Line Items]	'	'
Operating Loss Carry Forward Expiration Percent	12.00%	'

Note_12_Income_Taxes_Details_T

Note 12 - Income Taxes (Details) - The (Benefit) From Income Taxes Attributable to Loss From Continuing Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current tax expense (benefit):	'	'
State and local	($197,000)	($184,000)
Total current tax expense (benefit)	-197,000	-184,000
Total expense (benefit) from income taxes	($197,000)	($184,000)

Note_12_Income_Taxes_Details_T1

Note 12 - Income Taxes (Details) - The (Benefit) from Income Taxes Differed (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 12 - Income Taxes (Details) - The (Benefit) from Income Taxes Differed [Line Items]	'	'
Statutory benefit	($95,000)	($1,381,000)
Other non-deductible expenses	2,000	1,000
Increase in federal valuation allowance	30,000	1,317,000
	-197,000	-184,000
Sale of New Jersey (Member)	'	'
Note 12 - Income Taxes (Details) - The (Benefit) from Income Taxes Differed [Line Items]	'	'
Sale of New Jersey net operating loss carry forward	-197,000	-189,000
State [Member]	'	'
Note 12 - Income Taxes (Details) - The (Benefit) from Income Taxes Differed [Line Items]	'	'
Federal tax impact of state tax benefit, net	$63,000	$68,000

Note_12_Income_Taxes_Details_D

Note 12 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets	'	'
Allowance for doubtful accounts	$6	$6
Inventory reserve	115	45
Other	161	151
Total Current Assets	282	202
Long Term Assets (Liabilities)	'	'
Property, plant and equipment	209	203
Deferred royalty payments	5	10
Tax operating loss carry forwards	10,672	11,101
Tax credit carry forwards	217	225
Non-employee stock options	685	625
Other	-8	-8
Total Long Term Assets (Liabilities)	11,780	12,156
Gross Deferred Tax Asset (Liability)	12,062	12,358
Less: valuation allowance	($12,062)	($12,358)

Note_12_Income_Taxes_Details_O

Note 12 - Income Taxes (Details) - Operating Loss and Tax Credit Carry Forwards (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Federal:	'
Operating losses (expiring through 2032)	$31,308
Research tax credits (expiring through 2025)	168
Alternative minimum	28
State:	'
Net operating losses - Tennessee (expiring in 2027)	425
State [Member]	'
Federal:	'
Alternative minimum	$21

Note_13_Lease_Commitments_Deta

Note 13 - Lease Commitments (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Leases [Abstract]	'	'
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$95,800	'
Operating Leases, Future Minimum Payments, Due in Two Years	97,200	'
Operating Leases, Future Minimum Payments, Due in Three Years	98,700	'
Operating Leases, Future Minimum Payments, Due in Four Years	98,700	'
Operating Leases, Future Minimum Payments, Due in Five Years	34,200	'
Operating Leases, Rent Expense	$121,700	$66,900

Note_14_Legal_and_US_Regulator1

Note 14 - Legal and U.S. Regulatory Proceedings (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Note 14 - Legal and U.S. Regulatory Proceedings (Details) [Line Items]	'
Accrued Environmental Loss Contingencies, Current	$6,000
Restricted Cash and Cash Equivalents	54,000
Estimated Clean Up Costs (Member)	'
Note 14 - Legal and U.S. Regulatory Proceedings (Details) [Line Items]	'
Environmental Remediation Expense	$739,000

Note_15_Employee_Benefits_Deta

Note 15 - Employee Benefits (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	100.00%	'
Defined Contribution Plan, Minimum Annual Contribution Per Employee Percent	1.00%	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$17,500	$17,000
Defined Contribution Plan, Cost Recognized	93,000	71,000
First Portion [Member] | Matching by Participants [Member]	'	'
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3.00%	'
First Portion [Member]	'	'
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100.00%	'
Second Portion [Member] | Matching by Participants [Member]	'	'
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2.00%	'
Second Portion [Member]	'	'
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%	'
Catch-up Contribution, Max (Member)	'	'
Note 15 - Employee Benefits (Details) [Line Items]	'	'
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$5,500	$5,500

Note_17_2012_Private_Placement1

Note 17 - 2012 Private Placement (Details) (USD $)	1 Months Ended	12 Months Ended
	Dec. 21, 2012	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013	Sep. 28, 2012	Dec. 31, 2011	Dec. 05, 2007	Dec. 12, 2005
Note 17 - 2012 Private Placement (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Proceeds from Issuance of Private Placement	$2,000,000	$2,000,000	$7,213,000	$5,304,000	'	'	'	'	'
Common Stock, Shares, Issued	'	42,705,032	'	'	46,748,575	'	'	'	'
undefined	'	'	'	'	'	'	'	'	'10 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	387,201	782,259	'	'	354,546	881,331	1,235,877	175,000	'
Class of Warrant or Right, Exercise Price of Warrants or Rights	0.01	0.85	'	'	1.21	'	0.35	1.25	'
Registration Statement, Expected Deadline	'six	'	'	'	'	'	'	'	'
Registration Statement, Declared Effective, Months	'nine	'	'	'	'	'	'	'	'
Purchase Agreement (Member)	'	'	'	'	'	'	'	'	'
Note 17 - 2012 Private Placement (Details) [Line Items]	'	'	'	'	'	'	'	'	'
Common Stock, Shares, Issued	1,965,740	'	'	'	'	'	'	'	'
undefined	'10 years	'	'	'	'	'	'	'	'

Note_18_Asset_Purchase_Agreeme1

Note 18 - Asset Purchase Agreement (Details) (USD $)	0 Months Ended	12 Months Ended
	Feb. 02, 2013	Dec. 31, 2013
Asset Purchase Agreement Disclosure [Abstract]	'	'
Payments to Acquire Other Productive Assets	$1,400,000	'
Milestone Payment	400,000	'
Payments to Acquire Productive Assets	$1,800,000	'
Finite-Lived Intangible Asset, Useful Life	'15 years	'15 years
No-Compete Contract, Number of Years	'7 years	'

Note_19_Subsequent_Event_Detai

Note 19 - Subsequent Event (Details) (Subsequent Event [Member], USD $)	0 Months Ended
	Mar. 25, 2014	Mar. 03, 2014
	Chief Executive Officer [Member]
Note 19 - Subsequent Event (Details) [Line Items]	'	'
Number of ANDA Submissions	'	14
Officers' Compensation	$75,000	'